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Szakmai Beszámoló 
 
I. A PUMA-G receptor agyi vérkeringésben betöltött szerepével kapcsolatos vizsgálatok 
Elsı feladatunk az agyi véráramlás-mérési technika egérre történı adaptálása volt. Mivel e 
területen szegényesek az irodalmi adatok, elızetes kísérleteket végeztünk a mérési rendszer 
optimalizálására. Ennek során a következı feladatokat oldottuk meg: 
1.) Megfelelı anesztézia-protokoll kiválasztása. Pentobarbitál alkalmazásakor azt 
tapasztaltuk, hogy 70 µg/g ip. dózisban nem elegendı a mőtéti beavatkozáshoz, nagyobb 
mennyiségben alkalmazva viszont gyakran okoz légzés-, illetve szív-megállást. 
Ketamin/xylazin anesztézia hatására jelentısen csökkent az egerek artériás vérnyomása, ami 
kifejezetten elınytelen az agyi vérkeringés vizsgálata szempontjából. Az izofluránnal 
létrehozott inhalációs narkózis során azt tapasztaltuk, hogy bár az anesztézia mélysége 
megfelelı, az általános vérkeringési paraméterek pedig stabilak voltak, az agyi erek 
hypercapniára adott válaszreakciója majdnem teljesen eltőnt, aminek oka az volt, hogy az 
anesztézia már önmagában egy nagyfokú, NO által közvetített agyi vazodilatációt okozott. Az 
uretánnak ilyen hatását nem tapasztaltuk, de 2 mg/g dózisban ez is kisebb mértékő 
vérnyomás-csökkenést okozott, alacsonyabb dózisban viszont nem csillapította kellıképpen a 
mőtéti fájdalmat. Végül az alábbi protokollt találtuk optimálisnak és használtuk a további 
kísérletek során: mőtét során 1,5 % izoflurán majd a mérések elıtt 1,3 mg/g uretán iv. az 
izoflurán fokozatos elhagyása mellett. 
2.) Általános vérkeringési paraméterek (vérnyomás és szívfrekvencia) monitorozása, valamint 
intravénás anyagbeadás. Mivel az egerek ereinek kanülálására alkalmas mőanyag csövek 
nem vásárolhatók, kidolgoztuk, hogyan lehet PE50-es csövekbıl hılégfúvó segítségével 
megfelelı vaszkuláris kanülöket készíteni. 
3.) Hımérséklet-szabályozás. Azt tapasztaltuk, hogy az anesztézia a patkányokhoz képest az 
egerekben sokkal súlyosabb hımérséklet-szabályozási defektust okoz, ezért beszereztünk és 
beüzemeltünk egy automatikus testhımérséklet-szabályozó készüléket. 
4.) Agyi véráramlás-mérés. Elıkísérletekben kiválasztottuk a legalkalmasabb lézer-Doppler 
véráramlásmérı fejet az egerek parietális agykérgében történı mérésekhez. Az eredetileg 
patkányra tervezett sztereotaxikus készüléket adaptáltuk egérre. 
A fent említett metodológiai problémák megoldása elengedhetetlen feltétele volt annak, hogy 
kísérleteinket standardizált körülmények között, a légzési, a sav-bázis és a vérkeringési 
paraméterek fiziológiás tartományában végezzük. 
Ezután megkezdtük a nikotinsav agyi vérkeringésre kifejtett hatásának és ebben a PUMA-G 
receptorok szerepének a vizsgálatát. Elıször azt teszteltük, hogy 20, 50 és 200 µg/g iv. 
dózisban alkalmazott nikotinsav hogyan befolyásolja az agykérgi véráramlást. Azt 
tapasztaltuk, hogy a nikotinsav iv. alkalmazva nem okozott szignifikáns változást sem a 
szisztémás vérkeringésben, sem pedig az agyi véráramlásban (1. ábra). 
Feltételeztük, hogy az iv. nikotinsav hatástalanságának hátterében az állhat, hogy nem képes 
átjutni a vér-agy gáton. Ezért megismételtük kísérleteinket nikotinsav (0,1 és 1 µg/g) 
intracerebroventrikuláris (icv.) alkalmazásával is. Azt tapasztaltuk, hogy a nikotinsav icv. 
alkalmazva sem okozott szignifikáns változást sem a szisztémás vérkeringésben, sem pedig az 
agyi véráramlásban (2. ábra). 
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1. ábra. Az artériás középnyomás és az agykérgi véráramlás PUMA-G+/+ egerekben nikotinsav (200 µg/g, iv.) 
adása elıtt (0 min.) és után különbözı idıpontokban (n=7). 
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2. ábra. Az artériás középnyomás és az agykérgi véráramlás PUMA-G+/+ egerekben nikotinsav (1 µg/g, icv.) 
adása elıtt (0 min.) és után különbözı idıpontokban (n=10). 
Ezután megvizsgáltuk, hogy ha a PUMA-G receptor expresszióját fokozzuk (a kísérlet elıtt 
24 órával ip. adott 100 ng E. coli lipopoliszachariddal), kialakul-e a nikotinsav hatására a 
szisztémás vagy agykérgi vérkeringés bármilyen változása. Azt tapasztaltuk, hogy 200 µg/g 
iv. nikotinsav ilyen körülmények között alkalmazva sem okozott szignifikáns változást a 
szisztémás, ill. agykérgi vérkeringésben (3. ábra). 
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3. ábra. Az artériás középnyomás és az agykérgi véráramlás lipopoliszachariddal elıkezelt PUMA-G+/+ 
egerekben nikotinsav (200 µg/g, iv.) adása elıtt (0 min.) és után különbözı idıpontokban (n=11). 
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Végül azt vizsgáltuk, hogy a nagy dózisban (1 µg/g) icv. adott lipopoliszacharid (LPS) 
hatására kialakuló agyi hyperemia kialakulásában szerepe van-e a PUMA-G receptornak. Az 
LPS adását követıen 240 percig folyamatosan regisztráltuk a vérnyomást és agykérgi 
véráramlást, majd 200 µg/g nikotinsavat adtunk iv. és méréseinket további 35 percen 
keresztül folytattuk. LPS hatására a vérnyomás enyhe csökkenése ellenére az agykérgi 
véráramlás fokozódását tapasztaltuk, mely tovább folytatódott a nikotinsav adása után is. A 
vérkeringési paraméterek változásai azonban nem különböztek PUMA-G-/- állatokban a 
PUMA-G+/+ kontrollokban tapasztaltakhoz képest (4. ábra). 
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4. ábra. Az artériás középnyomás és az agykérgi véráramlás PUMA-G+/+ (felsı ábrák, n=6) és PUMA-G-/- (alsó 
ábrák, n=4) egerekben lipopoliszacharid (1 µg/g) majd nikotinsav (200 µg/g, iv.) adása elıtt és után. 
Eredményeink összességében arra utaltak, hogy a PUMA-G receptor nem játszik szignifikáns 
szerepet az agykérgi véráramlás szabályozásában sem élettani sem pedig kórélettani 
körülmények között. 
II. A PUMA-G receptor bırben játszott szerepével kapcsolatos vizsgálatok 
Az eredeti munkatervben szereplı kísérleteken kívül vizsgálatokat végeztünk a nikotinsav 
bır-véráramlásra gyakorolt hatásával kapcsolatban is. Ennek célja a véráramlás-fokozódást 
közvetítı sejtek azonosítása volt. Korábbi munkáinkban igazoltuk, hogy a PUMA-G receptor 
kifejezıdik a bırben található immunsejtekben és ezek közül valamelyik sejttípus közvetítheti 
a nikotinsav hatására kialakuló vazodilatációt. Leírtuk továbbá, hogy a hízósejtek nem 
játszanak szerepet a folyamatban. 
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Újabb vizsgálatainkra azáltal nyílt lehetıség, hogy az utóbbi években létrehoztak olyan 
egértörzseket, melyekben a humán diftéria-toxin receptor expresszálódik sejttípus-specifikus 
promoterek (CD11b, CD11c illetve Langerin) irányításával. Diftéria toxin szisztémás 
adásával a receptort expresszáló sejtek (makrofágok, dendritikus sejtek illetve epidermális 
Langerhans-sejtek) depletálhatók. Megállapítottuk, hogy sem a makrofágok sem pedig a 
dendritikus sejtek depléciója nem befolyásolja a nikotinsav hatására kialakuló véráramlás-
fokozódást (flush reakciót) a bırben. Ezzel szemben a Langerhans-sejtek depléciója majdnem 
teljesen eltüntette a nikotinsav okozta flush-t, de nem befolyásolta a prosztaglandin D2 
(PGD2) véráramlás-fokozó hatását. PUMA-G+/+ Langerhans sejtekben nikotinsav hatására 
fokozódott az intracelluláris Ca2+ koncentráció, mely hatás elmaradt PUMA G-/- sejtekben. 
Végezetül igazoltuk, hogy az epidermális Langerhans-sejtekben expresszálódnak a flush-
reakció közvetítéséért felelıs PGD2-t és PGE2-t szintetizáló enzimek. 
Eredményeink hozzásegítenek a nikotinsav-kezelés legkellemetlenebb mellékhatását 
közvetítı folyamatok feltárásához, egyúttal pedig felhívják a figyelmet a Langerhans-sejtek 
eddig ismeretlen élettani/kórélettani szerepére a bır véráramlásának szabályozásában. 
Ismert, hogy a nikotinsav zsírsejteken kifejtett antilipolitikus hatását a PUMA-G receptor 
közvetíti. Mivel a sebocyták is igen komplex lipidszintetikus tevékenységgel jellemezhetıek, 
megvizsgáltuk, hogy a nikotinsav miként befolyásolja ezen sejtek faggyútermelését. 
Transzgenikus riporter-egerek segítségével, valamint in situ hibridizációval igazoltuk a 
PUMA-G receptort kódoló gén expresszióját a bır faggyúmirigyeiben és a szebózus fityma-
mirigyben. Vad típusú (PUMA-G+/+) felnıtt hím egerek ivóvízébe 6 héten keresztül 0,3 % 
nikotinsavat adagolva azt tapasztaltuk, hogy a fityma-mirigy triglicerid-tartalma 
szignifikánsan (p=0,012) lecsökkent (0,28±0,06 %) a kontrollokéhoz (0,70±0,11 %) 
viszonyítva. Ezzel szemben PUMA-G-/- egerekben hasonló nikotinsav-kezelést követıen a 
triglicerid-tartalom (0,91±0,12 %) nem változott meg a kezeletlen állatokban mért szinthez 
(0,79±0,14 %) képest. Eredményeink szerint tehát a nikotinsav a PUMA-G receptor által 
közvetített mechanizmussal csökkenti a sebocyták zsírtartalmát egérben, ami felveti a PUMA-
G receptor agonisták alkalmazásának lehetıségét az acne és seborrhea kezelésére. 
III. Az agyi vérkeringés szabályozásával kapcsolatos vizsgálatok 
Endocannabinoidok cerebrovaszkuláris hatásainak vizsgálata 
Megvizsgáltuk, hogy miként befolyásolják az endogén cannabinoid vegyületek az agykéreg 
véráramlását fiziológiás körülmények között, valamint kombinált hypoxia/hypercapnia (H/H) 
során. Altatott felnıtt hím Wistar patkányokban az agykérgi véráramlást (CBF) a parietális 
kéregben laser-Doppler módszerrel mértük. Kísérleteink elsı szakaszában az 
endocannabinoidok felvételét gátló AM404 (10 mg/kg iv.) hatását vizsgáltuk a nyugalmi 
CBF-re. Kísérleteink második szakaszában azt vizsgáltuk, hogy a CB1-receptor antagonista 
AM251 miként befolyásolja az 5%O2-20%CO2-75%N2 gázkeverékkel kiváltott CBF-
emelkedést. 
AM404 hatására egy átmeneti CBF-fokozódást tapasztaltunk. Az áramlásfokozódással 
egyidejőleg csökkent az állatok légzésszáma, fokozódott az artériás CO2 és csökkent az O2 
tenzió, arra utalva, hogy az AM404 elsıdleges hatása légzésdepresszió volt. Ezután 
megvizsgáltuk az AM251 hatását a mesterségesen kiváltott H/H CBF-fokozó hatására. A 
CBF-emelkedést mind 3, mind pedig 10 mg/kg iv. AM251 szignifikánsan fokozta, míg a 
vehikulum hatástalannak bizonyult. 
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Eredményeink arra utalnak, hogy hypoxia és hypercapnia során az endocannabinoid 
felszabadulás véráramlás csökkenést okoz, aminek hátterében az excitatorikus glutamáterg 
neurotranszmisszió preszinaptikus gátlását feltételezzük. 
Az endogén szénmonoxid cerebrovaszkuláris hatásainak vizsgálata 
Az endogén szénmonoxid (CO) hembıl képzıdik a hemoxigenáz (HO) enzimek által 
katalizált reakció során. Kísérleteinkben a CO-nak az agyi erek tónusára és az agyszövet 
perfúziójára kifejtett hatásait vizsgáltuk. Az általában is igen magas HO aktivitást mutató 
agyszöveten belül a hypothalamusban kifejezetten nagymértékő az enzim expressziója, ezért 
elıször e régióban végeztük vizsgálatainkat. A CO közvetlen hatásai mellett a nitrogén 
monoxid szintetáz (NOS)- és és ciklooxigenáz (COX)-reakcióutakkal való kölcsönhatásaira is 
próbáltunk fényt deríteni. 
Igazoltuk, hogy a konstitutív endogén CO képzıdés egyrészt tónusosan gátolja a 
hypothalamikus NOS aktivitást, másrészt pedig stimulálja a PGE2–felszabadulást és e két 
úton keresztül indirekt módon képes befolyásolni a hypothalamus véráramlását. Nyugalmi 
körülmények között e két hatás egyensúlyban van, azonban NO-hiányos állapotban a PGE2 
által közvetített vazodilatátor hatás fokozottan érvényesül és hozzájárul a hypothalamus 
véráramlásának fenntartásához. 
Más agyi régiókban, pl. a parietális agykéregben az endogén CO NOS-t gátló hatása dominál 
és így véráramlás-csökkenést okoz. Leírtuk továbbá, hogy a más kutatócsoportok által 
korábban újszülött malacok vizsgálatával nyert kísérleti adatokkal ellentétben a HO–CO 
reakcióút felnıtt patkányokban nem járul hozzá szignifikánsan a hipoxia-, ill. hiperkapnia-
okozta agykérgi véráramlás-fokozódáshoz. 
Szfingolipid mdiátorok szerepe az a. carotis tónusának szabályozásában 
További kísérleteket végeztünk a szfingolipid mediátorok hatásaival kapcsolatban az arteria 
carotis válaszkészségére. A szfingomielinbıl szfingomielináz (SM) által katalizált reakció 
során képzıdı ceramid és a belıle szintetizálódó szfingolipid mediátorok az utóbbi évek 
kutatásai szerint számos élettani és kórélettani folyamatban játszanak fontos szerepet. 
Nemrégiben fokozott SM aktivitást írtak le endotoxémiás és krónikus szívelégtelenségben 
szenvedı betegek vérében és felmerült ennek kóroki szerepe az e betegségekben 
megfigyelhetı ér-diszfunkció kialakulásában. Kísérleteink célja kettıs volt: egyrészt a 
neutrális SM (nSM) hatásának vizsgálata az arteria carotis válaszkészségére, másrészt pedig a 
reaktív oxigén-szabadgyökök (ROS) szerepének tisztázása e hatás közvetítésében. Vad típusú 
(WT), szuperoxid dizmutázt túlexpresszáló transzgenikus (SODtg) és a NAD(P)H oxidáz 2-es 
izoformáját nem expresszáló NOX2ko egerekbıl izolált arteria carotis győrők válaszkészségét 
határoztuk meg izometriás körülmények között miográffal. Az érfal sejtjeinek ROS termelését 
dihidroethidinnel történı festéssel detektáltuk. 
Ceramiddal történı inkubáció az érfal valamennyi rétegében fokozott ROS felszabadulást 
okozott, és ez a hatás a simaizomban volt a legkifejezettebb. A különbözı genotípusú erek 
nyugalmi kontrakciós válaszai nem különböztek egymástól, azonban az acetilkolin (ACh) 
által kiváltott endothelium-függı relaxáció szignifikánsan erısebb volt a SODtg erekben 
jelezve, hogy a nyugalmi ROS-termelés konstitutívan gátolhatja az NO-függı érválaszokat. 
Mind a WT mind pedig NOX2ko erekben nSM csökkentette a fenilefrin kontrakciós és az 
ACh relaxációs hatását. A SODtg erekben elmaradt az nSM-okozta kontrakció-csökkenés, 
azonban az ACh relaxációs hatása gyengébb volt nSM jelenlétében. Eredményeink alapján azt 
a következtetést vontuk le, hogy az nSM ROS által közvetített, de NOX2-tıl független módon 
csökkenti az érsimaizom kontrakciós válaszait és ezáltal hozzájárulhat az adrenerg 
vazokonstriktorokkal szembeni rezisztencia kialakulásához szeptikus sokk késıi fázisában. 
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ABSTRACT 
Background: Low frequency (4-12 cpm) spontaneous fluctuations of the cerebrovascular 
tone (vasomotion) and oscillations of the cerebral blood flow (CBF) have been reported 
in several diseases associated with endothelial dysfunction. Since endothelium-derived 
nitric oxide (NO) suppresses platelet aggregation as well as vascular release of 
thromboxane A2, NO-deficiency is often associated with activation of thromboxane 
receptors (TP). In the present study we hypothesized that in the absence of NO, 
hypersensitivity of the TP-receptor mediated cerebrovascular signaling pathway promotes 
vasomotion. 
Methodology/Principal findings: In isolated rat middle cerebral arteries the TP-receptor 
agonist U-46619 in a concentration of 100 nM, which was without any effect under 
physiological conditions, induced sustained vasomotion after inhibition of the NO 
synthesis. Similarly, intravenous administration of 1 μg/kg U-46619 to anesthetized rats 
failed to induce any changes of the systemic or cerebral circulatory parameters under 
physiological conditions but aggravated CBF-oscillations after NO-blockade. 
Conclusion/Significance: These results indicate that hypersensitivity of the TP-receptor 
mediated signaling pathway is a pathogenic factor in the development of cerebral high-
amplitude vasomotion which may propagate to vasospasm in pathophysiological states 
associated with NO-deficiency. 
INTRODUCTION 
Low frequency (4-12 cpm) fluctuations of the cerebral oxygen availability in mammals 
were reported for the first time by Davis and Bronk in 1957 [1] and confirmed later in 
primates including humans (for review see: [2]). These fluctuations are termed 
“spontaneous” to indicate their independence of cardiac or respiratory cycles. In 1981 
Dóra and Kovách [3] showed similar oscillations in cerebrocortical NADH fluorescence 
which lagged by 2 sec behind the cortical vascular volume suggesting that the vascular 
event initiated the metabolic one. The concept that the low frequency metabolic 
oscillations of the brain are induced by variations of the cerebral blood flow (CBF) is also 
supported by observations in isolated cerebral vessels showing vasomotion in vitro [4-5]. 
Renewed interest in CBF oscillations was generated by studies in humans with laser-
Doppler flowmetry [6-7], transcranial Doppler sonography [8], functional MRI [9] and 
near infrared spectroscopy [10]. 
Vasomotional activity reflected by CBF oscillations has been reported in subarachnoid 
hemorrhage (SAH) before the onset of cerebral vasospasm and during recovery [11]. This 
indicates that overactivation of the mechanism(s) responsible for vasomotion may be 
involved in the pathogenesis of spastic contractions and the enhancement of 
vasomotional activity may predict the development of acute vasospasm. On the other 
hand, vasodilation (induced by hypercapnia or volatile anesthetics) promptly and 
reversibly suspends low frequency CBF oscillations [12-13] and the cerebrovascular 
endothelium also supresses vasomotion by releasing NO [2]. In accordance, enhanced 
CBF oscillations have been reported in pathophysiological states associated with 
decreased bioavailability of NO, such as SAH [11], traumatic brain injury [14] and 
hypertension [15]. 
Recent studies in isolated cerebral arteries have indicated the role of the thromboxane 
pathway in the functional changes induced by inhibition of NO synthesis [5,16-17]. This 
interaction is particularly interesting in the light of recent observations indicating that in 
NO-deficiency other prostanoids (e.g. prostacyclin) may also induce vascular smooth 
muscle effects via activation of the thromboxane (TP) receptor [18] and cerebrovascular 
expression of TP-receptors is enhanced after SAH [19]. In the present study we 
hypothesized that in NO-deficiency a hypersensitivity of the cerebrovascular TP-receptor 
mediated signaling pathway develops resulting in enhanced vasomotion and blood flow 
oscillations in the cerebral cortex. 
 
METHODS 
The experiments were performed in adult male Wistar rats (300-400 g) under the 
guidelines of the Hungarian Law of Animal Protection (243/1988) and all procedures 
were approved by the Semmelweis University Committee on the Ethical Use of 
Experimental Animals (590/99 Rh). The animals were anesthetized with urethane (1.5 
g/kg intraperitoneally), the depth of anesthesia was regularly controlled during the 
experiments by checking the corneal or plantar nociception reflex and additional urethane 
was administered intravenously (iv.) as necessary. The animals were spontaneously 
breathing through an intra-tracheal cannula. Catheters were inserted into both femoral 
arteries (for systemic arterial blood pressure measurement and for blood sampling) and 
into the left femoral vein (for drug administration). Body temperature was kept constant 
between 36-38 °C with a controlled heating pad. 
Systemic arterial pressure was recorded continuously on a polygraph (Model 7E, Grass, 
Quincy, MA, USA). Measurement of cerebrocortical blood flow (CoBF) has been 
performed by laser-Doppler (LD) flowmetry as described in detail elsewhere [20]. The 
head of the animals was fixed in a stereotaxic head holder with the nose 5 mm down from 
the interaural line. The skull of the parietal region was exposed and the bone was thinned 
over the parietal cortex on both sides with a microdrill, so that the lamina interna of the 
skull remained intact. Two LD probes were placed above the thinned skull at a 12°-angle 
to the vertical to provide an optimal view of the cortex (4 mm caudal from bregma, 5 mm 
lateral from midline). CoBF was measured with a two-channel blood flow monitor 
(MBF3D, Moor Instruments, UK) and was recorded continuously. The LD monitor was 
calibrated before each individual experiment with a constant movement latex emulsion. 
The laser light was in the infrared range (780 nm) and penetrated about 1 mm into the 
brain covering approximately 7 mm2 of the parietal region, so that the data acquired 
mostly represented the characteristics of the blood flow in the parietal cortex [20]. 
Animals were randomly assigned to two in vivo experimental groups. In the first (control) 
group systemic and cerebral circulatory parameters, as well as blood gas and acid-base 
values were determined before as well as for 75 minutes after an iv. bolus injection of 1 
ml/kg vehicle (saline). Thereafter the animals received the thromboxane receptor agonist 
U-46619 in a dose of 1 μg/kg iv., which in preliminary experiments was below the 
threshold of inducing any systemic or cerebral circulatory changes. The second group 
received first NG-nitro-L-arginine methyl ester (L-NAME) in a dose of 100 mg/kg iv. for 
the inhibition of NO synthesis and 75 minutes later U-46619 as described above. 
Previous studies have verified that L-NAME in the dose used in our present study 
effectively inhibits cerebral NOS activity [21]. The final measurements were performed 
in both experimental groups 25 minutes after the administration of U-46619. 
The in vitro experiments were performed in middle cerebral arteries (MCAs) supplying 
the parietal cortex, the site of the in vivo CoBF measurements. MCA segments were 
prepared from adult male Wistar rats as previously described [22] and studied in a 
conventional myograph system (610M, Danish Myo Technology A/S, Aarhus, Denmark). 
Effects of 100 nM U-46619 were determined on the isometric vascular tension in intact 
vessels and after NOS-blockade induced by 100 µM L-NAME. 
The Discrete Fourier transform (spectrum) of the time series obtained in vivo (CoBF) or 
in vitro (vascular tone) was calculated by Fast Fourier Algorithm (FFT) [23]. The 
calculations were executed in the Matlab environment which uses an adaptive version of 
the FFT, called FFTW [24]. The DC (zero frequency) component was eliminated from 
the spectrum by subtracting the mean value of time series from the samples and this way 
generating zero-mean time series. In order to identify the largest frequency component of 
the spectrum the interesting region was gated by an appropriate frequency window. 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA). Values are 
presented as mean ± SEM; n represents the number of animals or MCA segments. 
Statistical analysis was performed using repeated measures ANOVA followed by a 
Tukey post-hoc test. A P value of less than 0.05 was considered to be statistically 
significant. 
 RESULTS 
Baseline physiological parameters were within the normal range in both in vivo 
experimental groups (Table 1.). Neither iv. administration of saline nor that of the TP-
receptor agonist U-46619 in a dose of 1 μg/kg induced any significant changes in acid-
base, blood gas or systemic circulatory parameters in the control group (Table 1.). 
Furthermore, neither the average CoBF (Table 1.) nor its Fourier spectrum (Figure 1.) 
changed after the administration of saline or U-46619 in control animals. These 
observations confirmed that U-46619 in this dose has no significant effect on the 
systemic and cerebrocortical circulation under physiological conditions. 
In the “NOS blockade” group iv. administration of L-NAME had no significant effect on 
acid base or blood gas parameters but increased systemic blood pressure and decreased 
heart rate. These changes developed within 25 minutes after L-NAME and remained 
unaltered later even after the administration of U-46619 (Table 1.). The CoBF reduced by 
more than 30 % within the first 25 min of L-NAME administration but did not change 
further until the completion of the experiments (Table 1.). Low frequency CoBF 
oscillations, which were absent under resting conditions, developed after the 
administration of L-NAME with a dominant frequency of 144 ± 2 mHz and magnitude of 
5.9 ± 0.7 AU (Figure 2.). U-46619 significantly (p=0.017) increased the magnitude of 
these oscillations to 8.8 ± 0.9 AU without changing the dominant frequency (144 ± 3 
mHz) (Figure 2.). 
Experiments with the isolated MCAs showed similar results to the in vivo observations. 
In the control group no spontaneous vasomotion could be detected before or after 
administration of saline or 100 nM U-46619 (Figure 1.), indicating that U-46619 in this 
concentration fails to induce any significant effect on the vascular tension under 
physiological conditions. Administration of L-NAME alone did not change the vascular 
tone, and failed to induce vasomotion, except in one vessel out of ten (Figure 2.). In 
contrast, stimulation of the TP-receptors with 100 nM U-46619, which was without any 
effect in control vessels, induced strong vasomotional activity in all NOS-blocked MCAs 
(Figure 2.) 
 
DISCUSSION 
Our results indicate that activation of TP-receptors increases cerebral vasomotion and 
CBF oscillations in NO-deficiency. This observation is particularly interesting in the light 
of the large number of pathologic conditions associated with diminished release and/or 
biological effectiveness of NO, such as atherosclerosis, diabetes, hypertension, 
ischemia/reperfusion and SAH. Since NO suppresses platelet aggregation as well as 
vascular release of TXA2, NO-deficiency is often associated with activation of TP-
receptors. Therefore, experimental conditions of the present study mimicked features of 
cerebrovascular diseases. Vasomotion is often enhanced in these pathophysiological 
states although it is still a question of debate whether CBF oscillations represent the last 
attempt of the cerebral circulation to prevent neuronal hypoxia or it is already the first 
sign of disrupted regulation. Both of these interpretations can be supported by the 
observations that CoBF oscillations precede the onset of vasospasm in SAH [11]. 
NO reportedly suppresses the synthesis of TXA2 [25] and inhibition of NOS was recently 
reported to enhance TXA2 release from cerebrovascular endothelial cells [17]. This 
interaction between NO and TXA2 may explain why did NOS blockade by itself induce 
CoBF oscillations in vivo but failed to induce vasomotion in vitro, where the endogenous 
TXA2 was diluted in the large volume (8 ml) of the organ baths. However, the weak 
exogenous stimulation of the TP-receptors by 100 nM U-46619, which was without any 
effect under physiological conditions, induced strong vasomotion in the absence of NO 
indicating a hypersensitivity of the vessels to TXA2. Therefore, cerebral vasomotion and 
CoBF oscillations appear to be potentiated but not directly induced by the activation of 
TP-receptors. 
In a recent study we have shown that both the Gq/11 and the G12/13 heterotrimeric G 
proteins are involved in the mediation of TXA2-induced vasoconstriction [26]. However, 
the vascular effects of weak TP-receptor stimulation, like those applied in the present 
study, are primarily induced by the G12/13-mediated activation of the small G protein 
RhoA and Rho-kinase (Németh and Benyó, unpublished observations), the main 
signaling pathway of calcium-sensitization. Since vasomotion is induced by calcium 
waves in the smooth muscle [27], TP-receptor mediated calcium-sensitization can 
enhance the resultant changes of the vascular tension, which is the most plausible 
explanation of our findings. 
Why is this TP-receptor mediated mechanism enhanced in NO-deficiency? As noted 
above, the increased release of endogenous TXA2 by the cerebrovascular endothelium 
[17] can only partly explain our observations. In the cerebral circulation constitutive NO-
synthesis maintains a basal vasodilator tone, partly by inhibition of the vasoconstrictor 
TXA2-pathway [16]. TP-receptors are targets of cyclic GMP-dependent kinase (PKG) 
which induce desensitization by phosphorylation at Ser331 of the C-tail domain of the 
receptor [28-29]. Furthermore, NO also interferes with the signaling pathway coupling 
TP-receptor activation to the calcium sensitization of the vascular smooth muscle. For 
instance, NO reportedly inhibits calcium sensitization by PKG-mediated inhibition of 
RhoA [30-31] and telokin [32], as well as by inhibition of RhoA activation through 
protein kinase A (PKA)-dependent phosphorylation of Gα13 [33]. PKG can also inhibit 
calcium sensitization by phosphorylating directly the myosin phosphatase targeting 
subunit (MYPT1) at Ser695 resulting in the reduction of phosphorylation at the adjacent 
inhibitory Thr696 site [34-36], the target of Rho-kinase [37]. Therefore, in the absence of 
NO not only the TP-receptors but also these downstream signaling pathways will be 
released from the tonic inhibitory influence of NO resulting in sensitization of the smooth 
muscle contractile machinery to fluctuations induced by calcium waves. 
In conclusion, our results indicate that hypersensitivity of the TP-receptors and/or related 
downstream signaling pathways in the cerebrovascular smooth muscle contributes to the 
development of cerebral vasomotion and consequent blood flow oscillations after 
inhibition of NO synthesis. Pharmacological inhibition of this enhanced reactivity may be 
beneficial to prevent vasospasm in cerebrovascular disorders associated with NO-
deficiency. 
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FIGURE LEGENDS 
Figure 1. Weak activation of thromboxane receptors doesn`t alter cerebrocortical 
blood flow and cerebrovascular tension under physiological conditions. A Original 
recordings of the cerebrocortical laser-Doppler flux in vivo (upper panels, scale in 
Arbitrary Units) and isometric tension of the MCA in vitro (lower panels, scale in 
mNewtons) before (left panels) and after (middle panels) vehicle (saline) treatment as 
well as after administration of the TP-receptor agonist U-46619 (right panels). 
Quantitative analysis of slow wave oscillations in vivo (B) and in vitro (C) with discrete 
Fourier transformation. The dominant frequency and the corresponding magnitude of the 
Fourier spectrum are shown on the figure for the individual experiments. Large symbols 
indicate the averages ± SEM. 
Figure 2. Weak activation of thromboxane receptors induces strong vasomotion in 
the absence of NO. A Original recordings of the cerebrocortical laser-Doppler flux in 
vivo (upper panels, scale in Arbitrary Units) and isometric tension of the MCA in vitro 
(lower panels, scale in mNewtons) before (left panels) and after (middle panels) the 
inhibition NOS activity with L-NAME as well as after administration of the TP-receptor 
agonist U-46619 (right panels). Quantitative analysis of slow wave oscillations in vivo 
(B) and in vitro (C) with discrete Fourier transformation. The dominant frequency and 
the corresponding magnitude of the Fourier spectrum are shown on the figure for the 
individual experiments. Large symbols indicate the averages ± SEM. Note that the 
“Magnitude” scales in B and C are different from those in Figure 1B and 1C.  


Table 1. Cerebrocortical blood flow and physiological parameters in the two in vivo experimental groups at different time 
points of the experiments. 
 Exp. group 0 min. 25 min. 50 min. 75 min. 100 min. 
Cerebrocortical Blood 
Flow (AU) 
Control 399.1 ± 24.0 424.6 ± 30.7 449.0 ± 38.5 446.2 ± 33.4 438.3 ± 31.0 
NOS blocked 416.2 ± 13.0 285.7 ± 11.1***††† 271.8 ± 9.6***††† 286.0 ± 11.8***††† 274.4 ± 10.6***†††
Mean Arterial Pressure 
(mmHg) 
Control 97.9 ± 6.4 96.0 ± 4.0 92.1 ± 3.6 94.2 ± 6.2 95.4 ± 5.4 
NOS blocked 100.0 ± 9.3 156.3 ± 11.0***††† 156.6 ± 11.9***††† 155.3 ± 8.9***††† 147.6 ± 8.0***†††
Heart Rate (bpm) 
Control 410 ± 22 409 ± 47 400 ± 38 402 ± 41 386 ± 46 
NOS blocked 408 ± 46 385 ± 48 383 ± 48* 382 ± 49* 375 ± 14** 
PaCO2 (mmHg) 
Control 41.0 ± 6.8 41.8 ± 4.1 43.2 ± 3.4 41.7 ± 5.2 45.7 ± 6.6 
NOS blocked 43.7 ± 4.6 44.4 ± 2.9 42.6 ± 3.2 41.8 ± 4.4 41.2 ± 4.4 
PaO2 (mmHg) 
Control 96.9 ± 11.5 95.1 ± 10.5 90.9 ± 8.8 95.0 ± 11.1 97.7 ± 16.7 
NOS blocked 99.0 ± 13.6 97.9 ± 10.7 99.3 ± 10.1 102.3 ± 11.8 94.9 ± 11.4 
O2 Saturation (%) 
Control 96.5 ± 1.3 96.9 ± 0.7 96.1 ± 0.7 96.5 ± 1.0 96.5 ± 1.2 
NOS blocked 96.5 ± 1.5 96.4 ± 0.7 96.8 ± 0.8 97.1 ± 1.1 96.4 ± 1.3 
pH 
Control 7.34 ± 0.04 7.36 ± 0.04 7.34 ± 0.03 7.35 ± 0.03 7.33 ± 0.04 
NOS blocked 7.32 ± 0.05 7.31 ± 0.03† 7.33 ± 0.04 7.34 ± 0.03 7.34 ± 0.04 
Standard Base Excess 
(mmol/l) 
Control -3.7 ± 2.8 -2.0 ± 1.9 -3.1 ± 1.9 -2.1 ± 1.1 -1.9 ± 1.1 
NOS blocked -2.2 ± 2.0 -3.4 ± 2.6 -3.4 ± 2.0 -3.4 ± 1.9 -3.5 ± 1.9 
 
L-NAME and U-46619 were injected after the “0 min.” and “75 min.” measurements, respectively. 
The n was 7 in the control and 10 in the NOS blocked experimental groups. *, ** and *** indicate significant differences vs. the “0 min.” value (p<0.05, 0.01 and 
0.001, respectively). † and ††† indicate significant differences vs. the corresponding value in the control group (p<0.05 and 0.001, respectively). 
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ABSTRACT
The antidyslipidemic drug nicotinic acid (niacin) has been used
for decades. One of the major problems of the therapeutical
use of nicotinic acid is a strong cutaneous vasodilation called
flushing, which develops in almost every patient taking nicotinic
acid. Nicotinic acid-induced flushing has been shown to be
mediated by the nicotinic acid receptor GPR109A and to in-
volve the formation of vasodilatory prostanoids. However, the
cellular mechanisms underlying this short-term effect are un-
known. Here, we show that epidermal Langerhans cells are
essential for the cutaneous flushing response induced by nic-
otinic acid. Langerhans cells respond with an increase in
[Ca2]i to nicotinic acid and express prostanoid synthases
required for the formation of the vasodilatory prostanoids pros-
taglandin E2 and prostaglandin D2. Depletion of epidermal
Langerhans cells but not of macrophages or dendritic cells
abrogates nicotinic acid-induced flushing. These data unex-
pectedly identify epidermal Langerhans cells as essential me-
diators of nicotinic acid-induced flushing and may help to gen-
erate new strategies to suppress the unwanted effects of
nicotinic acid. In addition, our results suggest that Langerhans
cells besides their immunological roles are also involved in the
local regulation of dermal blood flow.
Nicotinic acid (niacin) is the oldest lipid-modifying drug
and induces a unique spectrum of changes in lipid and li-
poprotein levels (Carlson, 2005). Besides its ability to de-
crease triglyceride and low-density lipoprotein cholesterol
levels, it has the strongest HDL cholesterol-elevating activity
among the currently available lipid modifying drugs. Be-
cause a low HDL cholesterol level is an independent risk
factor for cardiovascular diseases, the HDL cholesterol ele-
vating effect of nicotinic acid has recently led to a renewed
interest in this drug (Carlson, 2006; Kontush and Chapman,
2006; Offermanns, 2006), and there is good evidence indicat-
ing a beneficial effect of nicotinic acid alone or in combination
with statins (Coronary Drug Project Research Group, 1975;
Brown et al., 2001; Taylor et al., 2004).
The major problem of oral nicotinic acid treatment is the
occurrence of a strong flushing phenomenon associated with
cutaneous vasodilation, which occurs in virtually all patients
and severely influences patients’ compliance. It has been
shown recently that the nicotinic acid receptor GPR109A
(HM74A in humans, PUMA-G in mice) mediates not only the
short-term metabolic effects of nicotinic acid but also the
flushing response (Tunaru et al., 2003; Benyo et al., 2005).
However, the cells and molecular mechanisms mediating
nicotinic acid-induced flushing are unclear.
The flushing response of nicotinic acid can be inhibited by
pretreatment with cyclooxygenase inhibitors (Andersson et
al., 1977; Svedmyr et al., 1977; Eklund et al., 1979; Kaijser et
al., 1979), and the levels of several vasodilatory prostanoids
like prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2)
and their metabolites are elevated after administration of
nicotinic acid (Eklund et al., 1979; Nozaki et al., 1987; Mor-
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row et al., 1989; Stern et al., 1991). These observations have
led to the hypothesis that prostanoids are involved in nico-
tinic acid-induced flushing. Pharmacological and genetic ev-
idence has been provided recently that PGD2 acting through
the PGD2 receptor and PGE2 acting via type 2 PGE2 receptor
and type 4 PGE2 receptor mediate the nicotinic acid-induced
flushing response (Benyo et al., 2005; Cheng et al., 2006).
The cells required for nicotinic acid-induced and prostan-
oid-mediated flushing, however, remain elusive. The ability
of topically applied nicotinic acid to induce locally restricted
hyperemia (Wilkin et al., 1985; Morrow et al., 1992) and the
fact that the nicotinic acid receptor GPR109A is expressed in
macrophages and other immune cells (Schaub et al., 2001)
suggest that immune cells of the skin are involved in the
flushing response. This is supported by data demonstrating
that MHC class II-positive skin cells express GPR109A and
that the lack of nicotinic acid-induced flushing response in
GPR109A-deficient mice can be restored by the transplanta-
tion of wild-type bone marrow (Benyo et al., 2005). We there-
fore systematically studied the potential involvement of var-
ious cell types in the cutaneous effects of nicotinic acid. By
conditional ablation of defined subpopulations of immune
cells and by the visualization of the local effects of nicotinic
acid, we show in the present study that epidermal Langer-
hans cells respond to nicotinic acid and mediate the flushing
response.
Materials and Methods
Mice. CD11b-DTR and CD11c-DTR mice were purchased (The
Jackson Laboratory, Bar Harbor, ME), and Langerin-DTR trans-
genic mice have been described previously (Bennett et al., 2005).
GPR109A-deficient mice were kindly provided by Klaus Pfeffer (Uni-
versita¨t Du¨sseldorf, Du¨sseldorf, Germany). Mice were housed in
temperature-controlled facilities on a 12-h light/dark cycle with ad
libitum food and water access. All experimental procedures were
performed in accordance with institutional guidelines of the Univer-
sity of Heidelberg (Heidelberg, Germany).
Measurement of Flush. Cutaneous blood flow was determined
as described previously (Benyo et al., 2005). In brief, anesthetized
mice were placed on their left side on a controlled heating pad, and
blood flow in the ear was determined with a laser-Doppler probe
(407; Perimed AB, Stockholm, Sweden). Original LDF recordings
were averaged for 1-s intervals, and the baseline LDF was deter-
mined before injection of the tested compound. All data are presented
as mean  S.E.M., and n indicates the number of experimental
animals. Statistical analysis of differences between flushing re-
sponses before and after diphtheria toxin (DT) treatment was per-
formed by Student’s paired t test, and p  0.05 was considered
significant. Nicotinic acid was prepared in 5% (2-hydroxypropyl)--
cylodextrin (Sigma, St. Louis, MO), and the pH of the solutions was
adjusted to 6.9 to 7.1 with 1 M NaOH. Prostaglandin D2 (Cayman
Chemical Co., Ann Arbor, MI) was dissolved in dimethyl sulfoxide
and diluted 20 times with saline.
DT Treatment. After control experiments, the CD11b-DTR,
CD11c-DTR, and Langerin-DTR transgenic animals were treated
with 25, 4, and 16 ng/g diphtheria toxin (Sigma), respectively, as
described previously (Jung et al., 2002; Bennett et al., 2005; Duffield
et al., 2005). DT was injected intraperitoneally 24 and 48 h before
retesting of the flushing responses. Wild-type littermate animals
were treated with the same protocol and served as controls. Between
two experiments the animals were allowed to recover for at least 1
week.
Isolation of Epidermal Sheets and Immunohistochemistry.
Mouse ears were dissected, split into ventral and dorsal sheets, and
incubated for 50 min in RPMI 1640 medium and 10 mM EDTA. The
epidermis was removed from the dermis using fine forceps and was
fixed on ice for 1 h in 4% paraformaldehyde/PBS. After permeabili-
zation with 0.2% Triton/PBS for 10 min at 25°C and two washes with
PBS for 10 min, the epidermal sheets were incubated with 10% goat
serum for 30 min. Polyclonal rabbit anti-PGE synthase 1, polyclonal
rabbit anti-PGE synthase 2 and monoclonal mouse PGD2 synthase
(all from Cayman Chemical) were each mixed with PE-labeled anti-
MHC II-IA/IE (BD PharMingen, San Diego, CA) in 10% goat serum/
PBS and incubated with epidermal sheets overnight at 4°C on a
rotator. Secondary FITC-labeled anti-rabbit and anti-mouse antibod-
ies were applied together with DAPI in 1.5% horse serum for 2 h on
a rotator. After washing, epidermal sheets were mounted and ana-
lyzed by fluorescence microscopy.
Fluorescence Activated Cell Sorting. Splenocytes were iso-
lated by collagenase digestion and passing through a 40-m nylon
mesh. Red blood cells were removed using Lympholyte-M (Cedarlane
Laboratories, Burlington, NC). Splenocytes were stained with FITC-
anti-CD11c and PE-labeled anti-F4/80 (BD PharMingen). Peritoneal
macrophages were obtained by peritoneal lavage and stained with
PE-labeled anti-F4/80 (BD PharMingen). All flow cytometric analy-
ses were performed using the FACSCalibur and Cell Quest software
(BD Biosciences, San Jose, CA).
Measurement of Intracellular [Ca2]. Epidermal sheets of
Langerin-GFP-DTR or GPR109A-deficient animals were incubated
in RPMI 1640 medium with 6 M Fura-2/acetoxymethyl ester/plu-
ronic acid (Invitrogen, Carlsbad, CA) and in the case of Puma-G
knockout together with FITC-labeled anti MHC II-IA/IE (BD
PharMingen) for 45 min. The epithelial sheets were placed dermal
side up in a perfusion chamber and immobilized with thin silk
threads tied to a steel ring. Epithelial sheets were superfused with
900 l of RPMI 1640 medium at a flow rate of 3.5 ml/min, and
stimulation was achieved by pipetting 100 l of a 10 concentrated
solution into the chamber. Excitation light was provided by a mono-
chromator (TILL Photonics, Gra¨felfing, Germany), and the fluores-
cence emission was captured by a cooled charge-coupled device cam-
era (Image QE; TILL Photonics) on an upright microscope (Olympus
BX51WI, Tokyo, Japan). The calcium concentration was visualized
in Langerhans cells that were identified by GFP or FITC fluores-
cence, respectively. Ratio images were collected at intervals every
500 ms. Imaging was controlled and analyzed with Tillvision Soft-
ware 4.0 (TILL Photonics).
Results
As reported previously, nicotinic acid-induced cutaneous
vasodilation can be observed and quantified in the mouse ear
using laser-Doppler flowmetry (Benyo et al., 2005; Cheng et
al., 2006). Intraperitoneal injection of nicotinic acid results
within a few minutes in a biphasic increase in the blood flow
that lasts for approximately 40 min. Based on the fact that
transplantation of wild-type bone marrow into GPR109A-
deficient mice can restore the ability of nicotinic acid to
induce flushing (Benyo et al., 2005), we tested the potential
involvement of various cutaneous immune cells in the nico-
tinic acid-induced flushing response. Because nicotinic acid
does not induce an increase in histamine levels (Morrow et
al., 1989), and because mast cell-deficient mice still respond
with flushing to nicotinic acid (Benyo et al., 2005), mast cells
are obviously not required for the flushing phenomenon. Be-
sides mast cells, dermal macrophages and dermal dendritic
cells are the major immune cells present in the dermis. To
examine their potential involvement in nicotinic acid-in-
duced flushing, we conditionally depleted macrophages and
dendritic cells using recently developed transgenic mouse
lines in which either the CD11c promoter element drives the
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expression of the human DT receptor in dendritic cells (Jung
et al., 2002) or in which diphtheria toxin receptor (DTR)
expression is restricted to macrophages by using the CD11b
promoter element (Duffield et al., 2005). Murine cells are
insensitive to DT because their DTR homolog does not bind
DT. In both CD11b-DTR and CD11c-DTR mice we were able
to show that the systemic administration of DT led to the
depletion of macrophages and dendritic cells, respectively
(Fig. 1A, B, F, and G). When DT-treated CD11b-DTR and
CD11c-DTR mice were injected with nicotinic acid, a normal
biphasic flushing response could be observed, which was
indistinguishable from the flushing response induced by nic-
otinic acid before DT treatment (Fig. 1, C–E and H–J). This
clearly indicates that neither macrophages nor dendritic cells
in the dermis or elsewhere in the body are involved in the
nicotinic acid-induced flushing response.
Another major immune cell type present in the skin is
epidermal Langerhans cells, which densely populate the epi-
dermal layer of the skin. By using a mouse line expressing
DTR under the control of the Langerhans cell-specific lange-
rin promoter (Bennett et al., 2005), we were able to study the
potential role of Langerhans cells in nicotinic acid-induced
flushing. DT treatment of Langerin-DTR mice resulted in
ablation of the Langerhans cell population from the epider-
mis of mice, whereas dermal dendritic cells were not affected
(Bennett et al., 2005) (Fig. 2, A and B). It is interesting that
depletion of Langerhans cells was accompanied by abroga-
tion of nicotinic acid-induced flushing, whereas Langerin-
DTR animals before DT treatment showed normal distribu-
tion of epidermal Langerhans cells and normal flushing
response to nicotinic acid (Fig. 2, C–E). Wild-type mice pre-
treated with DT under the same conditions as Langerin-DTR
transgenic mice exhibited a normal flushing response (data
not shown). Treatment of Langerin-DTR animals with DT
did not principally affect the ability of these animals to re-
spond with cutaneous vasodilation to other stimuli as, shown
Fig. 1. Effect of macrophage and den-
dritic cell depletion on nicotinic acid-
induced flushing. CD11b-DTR (A–E)
and CD11c-DTR transgenic mice
(F–J) were analyzed before or after
intraperitoneal injection of DT. A, B,
F, and G, verification of macrophage
and dendritic cell depletion. Cells har-
vested by peritoneal lavage (A and B)
or splenocytes (F and G) were ana-
lyzed by fluorescence-activated cell
sorting. C–E and H–J, original laser-
Doppler flow recordings and quantita-
tive analysis of the percentage of LDF
increase in response to intraperito-
neal administration of 200 g/g nico-
tinic acid in untreated or DT-treated
CD11b-DTR (C–E) and CD11c-DTR
mice (H–J).
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by the normal flushing response to the intraperitoneal injec-
tion of PGD2 (Fig. 2, F–H). Thus, epidermal Langerhans cells
are specifically required for the nicotinic acid-induced cuta-
neous vasodilation and are positioned upstream of PGD2
release.
To test whether Langerhans cells functionally respond to
nicotinic acid, we prepared epidermal sheets from ears of
Langerin-DTR mice, which express enhanced green fluores-
cent protein fused to DTR (Bennett et al., 2005), and loaded
epidermal cells with the Ca2 indicator Fura-2/acetoxy-
methyl ester. At the same time, Langerhans cells were visu-
alized by fluorescence microscopy (Fig. 3A). Exposure of
Fura-2-loaded epidermal sheets to 100 M nicotinic acid
resulted in a transient increase in [Ca2]i of Langerhans cells
(Fig. 3, B and C). Fura-2-loaded Langerhans cells in epider-
mal sheets from GPR109A-deficient mice, which were iden-
tified by staining with an anti-MHCII antibody, did not re-
spond with any increase in [Ca2]i to the application of
nicotinic acid but still responded to the Ca2 ionophore iono-
mycin (Fig. 3D).
Because PGD2 and PGE2 have been shown to be principal
mediators of the nicotinic acid-induced flushing response, we
tested whether epidermal Langerhans cells express prosta-
glandin D2 and prostaglandin E2 synthases. Staining of epi-
dermal sheets from mouse ears with specific antibodies di-
rected against murine PGD2 synthase and types 1 and 2
PGE2 synthases (mPGES-1 and mPGES-2) together with an
antibody against mouse MHCII showed the presence of both
PGD2 synthase and type 2 PGE synthase, whereas we were
unable to detect mPGES-1 (Fig. 4). The mPGES-2 enzyme
seemed to be exclusively expressed in epidermal Langerhans
cells, whereas prostaglandin D2 synthase was also detected
in other cells of the epidermis (Fig. 4).
Discussion
The nicotinic acid-induced flushing response is a phenom-
enon that was first described shortly after the discovery of
nicotinic acid as a vitamin (Spies et al., 1938; Goldsmith and
Cordill, 1943). The ability of nicotinic acid to induce a strong
cutaneous vasodilation has always been an obstacle in the
clinical use of nicotinic acid as a lipid-modifying drug. De-
spite the pharmacological importance of this phenomenon,
the underlying mechanism is still not clear. Based on the
recent observation that bone marrow-derived immune cells
in the skin mediate the nicotinic acid-induced flushing re-
sponse, we systematically studied the involvement of individ-
ual cell populations like dermal macrophages, dermal den-
dritic cells, and epidermal Langerhans cells, which are all
present at relatively high numbers in human and mouse skin
(Lenz et al., 1993; Dupasquier et al., 2004). Our data clearly
indicate that the nicotinic acid-induced flushing response is
mediated by epidermal Langerhans cells, whereas dermal
dendritic cells and macrophages are not required. Depletion
of Langerhans cells alone is able to prevent nicotinic acid-
induced flushing.
Previous studies have shown that PGD2 and PGE2 are
critically involved in the nicotinic acid-induced flushing re-
sponse (Benyo et al., 2005; Cheng et al., 2006). To test
Fig. 3. Epidermal Langerhans cells respond to nicotinic acid. Langerhans
cells were identified in epidermal sheets of untreated Langerin-DTRmice
by enhanced green fluorescent protein fluorescence (A), and sheets were
loaded with Fura-2 and exposed to 100 M nicotinic acid (B and C). D,
representative traces demonstrating the effect of nicotinic acid (100 M)
and ionomycin (Iono, 1 M) on [Ca2]i on MHCII-positive cells of epider-
mal sheets prepared from GPR109A-deficient mice. Values on the y-axis
indicate the measured 340/380-nm fluorescence ratio as an indicator of
the free intracellular [Ca2].
Fig. 2. Nicotinic acid-induced flushing requires the presence of epidermal Langerhans cells. Langerin-DTR transgenic mice were analyzed before or
after intraperitoneal injection of DT. A and B, verification of Langerhans cell depletion. Shown is an overlay of the light microscopical image and the
fluorescence image of epidermal sheets prepared from untreated (A) and DT-treated (B) Langerin-DTR mice, which were stained with PE-labeled
anti-MHCII antibodies. C–E, original laser-Doppler flow recordings and quantitative analysis of the percentage of LDF increase in response to
intraperitoneal administration of nicotinic acid in untreated or DT-treated Langerin-DTR mice. F–H, original laser-Doppler flow recordings and
quantitative analysis of the percentage of LDF increase after intraperitoneal administration of 2 g/g PGD2 in untreated or DT-treated Langerin-DTR
mice.
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whether Langerhans cells are principally able to synthesize
both prostanoids, we tested them for the expression of PGD2
and PGE2 synthases. We found both PGD2 synthase and the
constitutive type 2 PGE2 synthase (mPGES-2) to be ex-
pressed in epidermal Langerhans cells. The inducible type 1
PGE synthase form (mPGES-1) (Kudo and Murakami, 2005)
could, however, not be detected. This is consistent with ear-
lier findings showing that Langerhans cells are a major
source of prostanoids in the epidermis and that their main
prostanoid product is PGD2 whereas they are also able to
synthesize PGE2 (Ruzicka and Aubock, 1987; Rosenbach et
al., 1990).
Our finding that Langerhans cells respond to nicotinic acid
with a transient increase in the cytoplasmic Ca2 concentra-
tion suggests that activation of Gi through the nicotinic acid
receptor results in a G-mediated phospholipase C activa-
tion, a classic response of immune cells to the activation of
Gi-coupled receptors (Exton, 1996; Rhee, 2001). The tran-
sient increase in the cytoplasmic Ca2 concentration is a
major trigger of the activation of phospholipase A2 and sub-
sequent formation of arachidonic acid. Arachidonic acid is
then further metabolized by the ubiquitously expressed type
1 cyclooxygenase and both PGD2 and PGE2 synthases, which
are present in Langerhans cells. The release of PGD2 and
PGE2 from nicotinic acid-activated Langerhans cells then
results in vasodilation in the dermal papillae of the upper
dermis layer, which are just adjacent to the epidermis-dermis
junction close to the localization of Langerhans cells.
The nicotinic acid-induced flushing response is subject to a
tolerance phenomenon that can be observed within days after
repeated administration of nicotinic acid (Olsson, 1994). Tol-
erance is unlikely to develop on the basis of receptor desen-
sitization because the metabolic effects are stable even after
long-term administration of nicotinic acid (Olsson, 1994). It
is more likely that the downstream mechanisms specific for
the nicotinic acid-induced flushing response are involved. We
could rule out the possibility that tolerance to nicotinic acid-
induced flushing is due to any translocation of Langerhans
cells, because repeated administration of nicotinic acid did
not change the number of Langerhans cells per epidermal
area, although the vasodilatory effect had seized (data not
shown). It is therefore more likely that the nicotinic acid-
induced prostanoid formation in Langerhans cells undergoes
tachyphylaxis. This would be consistent with the observation
that the development of tolerance to nicotinic acid-induced
flushing is accompanied by a reduced formation of prosta-
noids (Stern et al., 1991). It has been described in the past
that patients with atopic dermatitis show a severely reduced
flushing response to topical application of nicotinic acid es-
ters (Uehara and Ofuji, 1977; English et al., 1987). Thus,
activation of Langerhans cells under certain pathological
conditions like atopic dermatitis (Leung et al., 2004) may
lead to a resistance of Langerhans cells to nicotinic acid-
induced prostanoid formation.
The observed link between the activation of epidermal
Langerhans cells and the regulation of blood vessel diameter
in the upper dermis raises the question of whether this
mechanism, in addition to its pharmacological significance,
has any physiological or pathophysiological role. There are
numerous transient and long-term forms of skin alterations
that go along with erythema. It will be interesting to study
the role of Langerhans cells not only in immunological re-
sponses of the skin but also in the local regulation of dermal
blood flow.
Our data clearly show that epidermal Langerhans cells
play a central role in the nicotinic acid-induced flushing
response by mediating the formation of vasodilatory prosta-
noids in response to activation by nicotinic acid. This study
provides new insight into the mechanism underlying the
clinical problem of nicotinic acid-induced flushing and may
provide the basis for new approaches aiming at the reduction
of this unwanted side effect. In addition, our data point to an
interesting new function of epidermal Langerhans cells in
the regulation of the local blood flow in the dermis, whose
potential physiological and pathophysiological role remains
to be further characterized.
Acknowledgments
We are grateful to Sabrina Zwykiel and Marie Sucha´nkova´ for
technical assistance and to Rose LeFaucheur for secretarial assis-
tance.
Fig. 4. Expression of prostanoid synthases in epidermal Langerhans
cells. Epidermal sheets from wild-type mice were stained with antibodies
against MHCII and mPGES-1 (A) or mPGES-2 (B) or PGD2 synthase (C,
PGD2-S). Scale bars: top, 50 m; bottom, 5 m.
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Available online 11 December 2006The aim of our study was to investigate the adaptation of the hypothalamic circulation to
chronic nitric oxide (NO) deficiency in rats. Hypothalamic blood flow (HBF) remained
unaltered during chronic oral administration of the NO synthase (NOS) inhibitor NG-nitro-
L-arginine methyl ester (L-NAME, 1 mg/ml drinking water) although acute NOS blockade by
intravenous L-NAME injection (50 mg/kg) induced a dramatic HBF decrease. In chronically
NOS blocked animals, however, acute L-NAME administration failed to influence the HBF.
Reversal of chronic NOS blockade by intravenous L-arginine infusion evoked significant
hypothalamic hyperemia suggesting the appearance of a compensatory vasodilator
mechanism in the absence of NO. In order to clarify the potential involvement of
vasodilator prostanoids in this adaptation, cyclooxygenase (COX) mRNA and protein
levels were determined in the hypothalamus, but none of the known isoenzymes (COX-1,
COX-2, COX-3) showed upregulation after chronic NOS blockade. Furthermore, levels of
vasodilator prostanoid (PGI2, PGE2 and PGD2) metabolites were also not elevated.
Interestingly, however, hypothalamic levels of vasoconstrictor prostanoids (TXA2 and
PGF2α) decreased after chronic NOS blockade. COX inhibition by indomethacin but not by
diclofenac decreased the HBF in control animals. However, neither indomethacin nor
diclofenac induced an altered HBF-response after chronic L-NAME treatment. Although
urinary excretion of PGI2 and PGE2 metabolites markedly increased during chronic NOS
blockade, indicating COX activation in the systemic circulation, we conclude that the
adaptation of the hypothalamic circulation to the reduction of NO synthesis is independent
of vasodilator prostanoids. Reduced release of vasoconstrictor prostanoids, however, may
contribute to the normalization of HBF after chronic loss of NO.
© 2006 Elsevier B.V. All rights reserved.Keywords:
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Acute inhibition of nitric oxide (NO) synthesis causes
sustained hypertension accompanied by a marked reduction
of the cardiac output and regional blood flow, including the
perfusion of the heart (Shah and MacCarthy, 2000) and brain
(Faraci and Heistad, 1998). During chronic NO synthase (NOS)
blockade, however, the coronary and the cerebral blood
flows return to the normal level although the vasoconstric-
tion in other organs remains unchanged (Benyó et al., 1995;
Huang et al., 1995; Ito et al., 1995; Kelly et al., 2000; Puybasset
et al., 1996; Tayama et al., 1998). In accordance, endothelial
NOS (eNOS) knockout mice show normal blood flow in the
heart (Gödecke et al., 1998) and brain (Atochin et al., 2003)
indicating that the circulation of these organs is able to
adapt to chronic NO deficiency. In case of the coronary
circulation, it is well established that a vasodilator prosta-
noid, presumably prostacyclin, may function as a compen-
satory factor after the chronic loss of NO (Beverelli et al.,
1997, Lacza et al., 2003; Marcelín-Jiménez and Escalante,
2001; Puybasset et al., 1996). The mechanism of the
adaptation of the cerebral circulation to chronic NO defi-
ciency is far less understood. Vasodilator prostanoids,
released constitutively from brain microvessels (Gecse et al.,
1982; Kis et al., 1999; Kövecs et al., 2001; Parfenova et al.,
2002; Peri et al., 1995), are apparently involved in the
maintenance of the resting cerebral blood flow in some species
including humans and rats (Busija, 2002; Leffler, 1997) and
enhancement of their influence may serve as a reserve
regulatory mechanism in NO deficiency. We have observed a
significant increase of the prostacyclin and prostaglandin E2
levels in the cerebrospinal fluid of rats after acute NOS
inhibition (Lacza et al., 2001b and unpublished observa-
tions), which may indicate the activation of a prostanoid
mediated compensatory mechanism in NO deficiency. In a
recent study, pial arteriolar relaxations in response to
acetylcholine or hypercapnia were improved during chronic
as compared to acute NOS blockade in female rats and the
improvement of the vasoreactivity was reversible by
indomethacin indicating the augmentation of the prosta-
noid contribution to these vasodilator responses in chronic
NO deficiency (Xu et al., 2003).Table 1 – Baseline physiological parameters in the different ex
Experimental group
(acute treatment)
I. L-NAME II. L-Arginine
Subgroup (chronic
pretreatment)
Control
(n=11)
L-NAME
(n=7)
Control
(n=12)
L-NAME
(n=12)
MABP (mmHg) 91±3 133±6*** 98±4 140±7***
PO2 (mmHg) 93±2 98±4 87±2 84±2
O2 sat. (%) 96.6±0.3 97.4±0.3 95.7±0.2 95.7±0.2
PCO2 (mmHg) 39.5±1.5 44.2±1.4 41.9±0.6 37.9±1.1
pH 7.37±0.02 7.40±0.01 7.35±0.01 7.38±0.01
Mean arterial blood pressure (MABP) as well as O2 and CO2 tensions (P
determined before acute treatment with the respective drug or vehicle. * a
values (p<0.05 and 0.001, respectively).The aim of our present study was therefore to clarify the
role of COX pathways in the adaptation of the cerebral
circulation to NO deficiency. We have focused on the
hypothalamic circulation, since in our earlier studies the
hypothalamic blood flow (HBF) was shown to normalize
within 1 week after the onset of the chronic NOS blockade
(Benyó et al., 1995). Furthermore, in this brain region relatively
high COX expression has been demonstrated (O'Banion, 1999;
Kis et al., 2004; Simmons et al., 2004) and prostanoid release
reportedly contributes to the maintenance of the resting HBF
of rats under physiological conditions (Dahlgreen et al., 1981;
Gerozissis et al., 1983; McCulloch et al., 1982).2. Results
During the 1-week pretreatment period, the daily water intake
was not different between control (n=54) and L-NAME-treated
(n=48) animals (101±7 vs. 96±4 ml/kg/day, respectively). In
animals subjected to NOS blockade, the average L-NAME
consumption was 96±4 mg/kg/day. After 1 week of L-NAME
pretreatment, the animals showed marked hypertension
(Table 1), but the HBF remained unchanged (0.86±0.04 vs.
0.86±0.04 ml/g/min in controls) in spite of the markedly
reduced hypothalamic NOS activity (1.19±0.16 vs. 4.85±
1.19 pmol citrulline/mg protein/min, p=0.003). Baseline arter-
ial blood gas and acid–base parameters showed no significant
differences between the control and the L-NAME pretreated
experimental groups (Table 1).
Acute NO blockade achieved by intravenous injection of
high dose (50 mg/kg) L-NAME induced marked hypertension
(Fig. 1A) and reduction of the HBF (Fig. 1B) in control animals
(n=11) but had no significant effect after chronic NOS blockade
(n=7) indicating the appearance of an NO-independent
mechanism in the maintenance of the HBF during chronic
NO deficiency (Figs. 1A and B).
Intravenous L-arginine administration (30 mg/kg initial
bolus followed by 10 mg/kg/min infusion) was without any
significant effect on the mean arterial blood pressure (MABP),
HBF, arterial blood gas tensions or pH in control animals
(n=11, Figs. 2A and B). This observation is consistent with our
previous report in cats (Kovách et al., 1992) and indicates thatperimental groups
III. Diclofenac IV. Indomethacin V. Vehicle
Control
(n=8)
L-NAME
(n=10)
Control
(n=17)
L-NAME
(n=13)
Control
(n=6)
L-NAME
(n=6)
93±6 130±3*** 94±4 125±3*** 91±5 120±5*
101±2 100±3 95±2 99±3 102±4 97±2
97.4±0.2 97.3±0.3 96.5±0.3 96.6±0.3 96.9±0.4 96.7±0.3
42.3±1.0 42.3±1.0 44.8±0.7 41.2±1.1 43.7±3.2 42.9±1.3
7.38±0.01 7.38±0.01 7.33±0.01 7.31±0.01 7.32±0.03 7.33±0.02
O2 and PCO2), O2 saturation and pH of arterial blood samples were
nd *** indicate significant differences vs. the corresponding “control”
Fig. 2 – L-Arginine administration normalizes the blood
pressure and elevates the hypothalamic blood flow over its
physiological level in chronically NOS blocked animals. Mean
arterial blood pressure (A) and hypothalamic blood flow (B)
before (0 min) as well as 10, 20 and 40 min after the onset of
intravenous L-arginine infusion in control (open circles,
n=12) and chronically L-NAME pretreated rats (filled circles,
n=12). ***p<0.001 vs. “0 min”.
Fig. 1 – Acute L-NAME administration induces marked
hypertension and reduction of the hypothalamic blood flow
in control but not in chronically NOS blocked animals. Mean
arterial blood pressure (A) and hypothalamic blood flow (B)
before (0 min) as well as 10, 20 and 40 min after intravenous
injection of 50 mg/kg L-NAME in control (open circles, n=11)
and chronically L-NAME pretreated rats (filled circles, n=7).
***p<0.001 vs. “0 min”.
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NO production. L-Arginine, however, was shown to reverse
L-NAME-induced cerebrovascular NOS-inhibition in a pre-
vious study (Sándor et al., 1994), and therefore we analyzed
its effect also in chronically L-NAME pretreated animals
(n=12). L-Arginine infusion normalized the MABP (Fig. 2A)
and at the same time evoked marked hypothalamic
hyperemia (Fig. 2B), without changing arterial blood gas or
acid–base parameters (data not shown). Since reversal of
the NOS blockade by L-arginine elevated the HBF over its
normal level (in spite of the reduction of the MABP to its
physiological level), it was reasonable to hypothesize that a
compensatory vasodilator mechanism has been activated in
the hypothalamic vasculature during chronic NO deficiency.
The potential involvement of COX isoenzymes and vasodi-lator prostanoids in this adaptation process has been
addressed in the second part of the study.
During chronicNOS blockade, the urinary concentrations of
prostacyclin and prostaglandin E2 metabolites increased sig-
nificantly, indicating the activation of COX pathways in the
systemic circulation (Fig. 3). In the hypothalamus of control
rats, RT-PCR revealed the constitutive expression of all three
known COX isoenzymes. Chronic NOS blockade, however, did
not induce upregulation of any of the mRNAs (Fig. 4A).
Consistently, the COX-1 and COX-2 protein levels were not
significantly different in L-NAME pretreated and control
animals (Fig. 4B). Furthermore, levels of vasodilator prosta-
noids in the hypothalamus did not change after chronic NOS
blockade (Table 2). Interestingly, however, the concentration of
Fig. 4 – Chronic NOS blockade does not influence the mRNA
and protein levels of COX isoenzymes in the hypothalamus.
(A) Semiquantitative RT-PCR indicating equal expression of
COX-1, COX-2 and COX-3 mRNA in the hypothalamus of
control (open bars, n=4) and chronically L-NAME pretreated
(filled bars, n=4) rats. Densitometric analysis of the RT-PCR
results normalized by β-actin. (B) Western blot analysis
indicating equal expression of COX-1 and COX-2 proteins in
the hypothalamus of control (open bars, n=6) and chronically
L-NAME pretreated (filled bars, n=6) rats. Densitometric
analysis of the Western blot results normalized by β-actin.
Fig. 3 – Chronic L-NAME administration increases the
production of vasodilator prostanoids. Urinary
concentrations of prostacyclin (PGI2, panel A) and
prostaglandin E2 (PGE2, panel B) metabolites in control (open
circles, n=5) and in L-NAME-treated (filled circles, n=5) rats
before (“Day 0”) and for 1 week after the onset of the
treatment. Values are normalized with the urinary creatinine
content. *p<0.05, **p<0.01 vs. “Day 0”.
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in the hypothalamus of L-NAME pretreated animals (Table 2).
COX inhibition by diclofenac (10 mg/kg iv) did not affect
HBF or other physiological variables in control (n=8) or
L-NAME-treated animals (n=10, Fig. 5A). In contrast, indo-
methacin (5 mg/kg iv) significantly reduced the HBF in control
rats (n=17, Fig. 5B)without changing theMABPor arterial blood
gas and acid–base parameters (data not shown). However, the
HBF-decreasing effect of indomethacin was not enhanced in
L-NAME pretreated animals (n=13, Fig. 5B). The vehicle of
indomethacin (2 ml/kg saline iv) did not influence either the
HBF or any other measured variables (data not shown). These
results altogether indicate that the adaptation of the hypotha-
lamic circulation to the reduction of NO synthesis is indepen-
dent of vasodilator prostanoids. Reduction of vasoconstrictorprostanoid release, however, may significantly contribute to
the normalization of the HBF after the loss of NO.3. Discussion
Chronic NOS blockade in normotensive rats is a well
established model of specific vascular dysfunction and
hence of early vascular disease, since several pathophysiolo-
gical states including essential hypertension, atherosclerosis
and vasospasm are associated with some degree of deficiency
of NO production or action (Faraci and Heistad, 1998). In case
of endothelial damage or other NO-depleting situations,
alternative vasodilator mechanisms may be upregulated in
order to compensate for the loss of NO. Characterization of
these compensatory mechanisms may help to improve
therapeutic strategies in cardiovascular diseases.
Previous studies have indicated the ability of the cerebral
circulation to adapt to chronic NO deficiency. First, it has
been demonstrated that the resting cerebral blood flow,
Fig. 5 – The effect of COX-inhibition by diclofenac or
indomethacin on the hypothalamic blood flow is not
impaired in animals subjected to chronic NOS blockade.
Hypothalamic blood flow before (0 min) as well as 10, 20 and
40 min after intravenous injection of 10 mg/kg diclofenac (A)
or 5 mg/kg indomethacin (B) in control (open circles, n=8 and
17 on panels A and B, respectively) and chronically L-NAME
pretreated rats (filled circles, n=10 and 13 on panels A and B,
respectively). ***p<0.001 vs. “0 min”.
Table 2 – Prostanoid concentrations (pg/mg tissue) in the
hypothalamus of control and L-NAME pretreated rats
Control (n=9) L-NAME (n=9)
6-Keto-Prostaglandin F1α 9.8±1.9 9.3±2.3
Prostaglandin E2 13.6±1.8 11.6±2.2
Prostaglandin D2 11.6±1.3 12.2±2.9
Thromboxane B2 40.2±4.2 26.1±4.1 ⁎
Prostaglandin F2α 37.7±3.9 18.6±3.9 ⁎⁎
⁎ p<0.05.
⁎⁎ p<0.01 vs. the corresponding “control” values.
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returns to its physiological level during chronically dimin-
ished NO synthesis (Atochin et al., 2003; Benyó et al., 1995;
Huang et al., 1995; Kelly et al., 2000). Second, chronic NOS
blockade influences less severely the cerebral vasodilator
responses evoked by hypercapnia, acetylcholine or NMDA
than the acute blockade (Pelligrino et al., 1996; Wang et al.,
1994; Xu et al., 2003). In the present study, although we were
unable to identify the compensatory mechanism(s) respon-
sible for the normalization of the hypothalamic blood flow,
we have clarified three important aspects of the adaptation
during chronic NO deficiency.
First, our observation that acute NOS blockade by L-NAME
infusion induced a dramatic HBF decrease in control but not
in chronically L-NAME-treated animals clearly indicates that
during chronic NO deficiency an NO-independent vasodilator
mechanism is involved in the maintenance of the HBF. This
conclusion is not obvious since the constitutive NOS activity
of the hypothalamus is only reduced by approximately 90%
during chronic oral L-NAME treatment (Benyó et al., 1995).
Taken into account that in case of diminished NO production
the cerebrovascular reactivity to NO increases (Kovách et al.,
1992; Moncada et al., 1991), the remnant 10% NOS activity
could contribute significantly to the maintenance of the
cerebral blood flow. Indeed, acute L-NAME treatment was
shown to reduce the blood flow in the neocortex, hippo-
campus and striatum of rats subjected to chronic NOS
blockade (Kelly et al., 1995), indicating that the remnant NO
production contributes to the maintenance of the blood flow
in these brain regions. Our results, however, indicate the
importance of an NO-independent mechanism in the nor-
malization of the hypothalamic blood flow during chronic
NOS blockade.
Second, the observation that reversal of the chronic NOS
blockade by L-arginine infusion elevates the HBF over its
normal level (in spite of the reduction of the MABP to its
physiological level) suggests the appearance of a vasodilator
mechanism, which is activated to compensate the loss of NO.
This has to be a very effective mechanism, since the high
regional blood flow increase during simultaneous arterial
pressure decrease indicates a remarkable reduction of the
cerebrovascular resistance in the hypothalamus. Numerous
observations in different experimental systems indicated that
prostacyclin may act as a backup vasodilator in chronic NO
deficiency. For instance, elevated plasma levels of prostacy-
clin and increased urinary excretion of the prostacyclin
metabolite 6-keto-prostaglandin F1α were reported after
chronic inhibition of NOS in rats (Cao et al., 1999; Danielsonand Conrad, 1996; Henrion et al., 1997; Tomida et al., 2003).
Furthermore, the endothelium-dependent relaxation by bra-
dykinin was sensitive to indomethacin in coronary arteries of
dogs subjected to chronic NOS blockade but not in controls
(Puybasset et al., 1996). A bradykinin-induced increase in
prostacyclin productionwas greater in coronary arteries taken
from nitro-L-arginine-treated dogs, which difference was
attributable to the upregulation of the endothelial COX-1
isoform during chronic inhibition of NOS (Beverelli et al., 1997,
Puybasset et al., 1996).
The third conclusion of our present study is, however, that
prostacyclin or other vasodilator prostanoids are not involved
in the adaptation of the hypothalamic circulation to chronic
NO deficiency. Although we have observed increased urinary
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chronic NOS blockade, the hypothalamic levels of these
prostanoids remained unchanged. Furthermore, none of the
COX isoforms showed an increased expression in the
hypothalamus of rats subjected to chronic L-NAME treatment.
In accordance, the influence of indomethacin or diclofenac on
the HBFwas not changed after chronic NOS blockade. All these
data clearly indicate that neither prostacyclin nor any other
vasodilator prostanoids play a significant role in the adapta-
tion of the hypothalamic circulation to chronic NO deficiency.
We have observed a significant reduction in the hypotha-
lamic levels of vasoconstrictor prostanoids after chronic NOS
blockade. This finding is particularly interesting in the light of
our previous observations showing that the cerebral vasocon-
striction induced by inhibition of the resting NO synthesis is
partly due to the increased reactivity of the cerebral vessels to
TXA2 (Benyó et al., 1998; Lacza et al., 2001a). During chronic
NOS blockade, however, the reduction of vasoconstrictor
prostanoid release may compensate this vascular hyperreac-
tivity and contribute to the normalization of the cerebral
vascular resistance and blood flow.
A further interesting finding of the present study is the
difference between the effects of indomethacin and diclofenac
on the resting HBF. Similar differences between the effective-
ness of these two COX inhibitors were reported previously:
indomethacin but not diclofenac inhibited the cerebral
hyperemic response to hypercapnia (Quintana et al., 1988)
and to acetazolamide-induced extracellular acidosis (Wang et
al., 1993) in rats. Both compounds, in doses used in our present
and the above cited studies, were shown to inhibit prostanoid
production in the rat brain (Abdel-Halim et al., 1978). However,
indomethacin was also reported to inhibit cerebrovascular
prostacyclin receptors, which effect could explain its stronger
influence on the resting HBF (Parfenova et al., 1995). The
difference of the relative potencies of these inhibitors towards
the different COX isoenzymes, i.e., the higher affinity of
indomethacin to COX-1 and diclofenac to COX-2 (Chandrase-
kharan et al., 2002; Mitchell et al., 1994), is also a possible
explanation for the different HBF-effects. Recent observations
that COX-1-deficient mice show diminished blood flow in
some brain regions including the hypothalamus (Niwa et al.,
2001) also suggest that this isoenzymemediates the release of
vasodilator prostanoid(s) influencing the resting cerebrovas-
cular tone.
In conclusion, the present study demonstrates that
during chronic NO deficiency the hypothalamic blood flow
remains unaltered and activation of one or more vasodilator
mechanisms appear to be responsible for this adaptation.
Constitutive prostanoid release, presumably by COX-1, con-
tributes to the maintenance of the hypothalamic blood flow
under physiological conditions, but the influence of this
mechanism is not enhanced during chronic NO deficiency.
Although the enhanced urinary excretion of PGI2 and PGE2
metabolites indicates COX activation in the systemic circula-
tion during chronic NOS blockade, we conclude that the
adaptation of the hypothalamic circulation to the reduction
of NO synthesis is independent of vasodilator prostanoids.
Reduced release of vasoconstrictor prostanoids, however,
may significantly contribute to the normalization of HBF
after chronic loss of NO.4. Experimental procedures
All investigations were performed in adult male Wistar rats
(b.w. 300–400 g) under the guidelines of the Hungarian Law
of Animal Protection (243/1988) and approved by the Semmel-
weis University Committee on the Ethical Use of Experimental
Animals (590/99 Rh). During the pretreatment period, the
animals were housed individually and drinking either normal
tap water or a 1 mg/ml L-NAME solution for 1 week.
The in vivo experiments were carried out in 102 rats
anesthetized with Urethane (1.3 g/kg ip; Sigma, St. Louis, MO,
USA) and spontaneously breathing via a trachea cannula.
Catheters were inserted into both femoral arteries (tomeasure
blood pressure and for blood sampling) and into the left
femoral vein for drug administration. The skull was fixed in a
stereotaxic head-holder. Body temperature was kept constant
between 36 and 38 °Cwith a controlled heating lamp. Systemic
arterial pressure was continuously recorded on a polygraph
(Model 7E, Grass, Quincy, MA, USA). Hypothalamic blood flow
(HBF) was determined by using Aukland's H2-gas clearance
method (Aukland et al., 1964), as described (Horváth et al.,
2003). Briefly, a 100-μm in diameter Teflon-coated Pt electrode
with a 1-mm bare tip was introduced stereotactically into the
ventromedial hypothalamic area. H2 washout curves were
produced by H2-gas inhalation and were recorded on the
polygraph. Bi-exponential analysis of the washout curves by
a computer program based on the Marquardt algorithm
(Marquardt, 1963) was used to calculate the HBF values.
Blood gas parameters (PCO2, PO2, O2 saturation) and pH in
femoral arterial samples were measured by a Radiometer
Blood Gas Analyzer (ABL-300, Copenhagen, Denmark) at the
times of HBF determinations. Mean arterial blood pressure
(MABP) was determined at the same time. After the last
measurements, the anesthetized animals were rapidly exsan-
guinated and hypothalamic tissue samples were excised and
frozen rapidly. Total hypothalamic NOS activity was mea-
sured on the basis of the formation of labeled citrulline from
labeled L-arginine (Nagy et al., 2000, Sándor et al., 1994). Tissue
samples were homogenized in brain homogenizing solution
containing 50 mM Tris–HCl (pH 7.4), 0.3 M sucrose, 0.1 mM
EDTA, 1 mM dithioerythritol and 1 mM phenyl-methyl-
sulfonylfluorid (PMSF, protease inhibitor). Homogenates
were added to the samples containing 5 mM HEPES, 1 mM
NADPH, 10 μM tetrahydrobiopterin, 30 μM calmodulin, 2.5 mM
CaCl2 at pH 7.4 and reaction was initiated by adding 20 μM 3H-
arginine (all final concentrations). After 30min incubation, the
reaction was stopped, samples were put onto 2-cm Dowex-
50×8 resin columns and eluates were mixed with 5-ml
dioxane-based scintillation fluid and measured in a Beckman
TriCarb liquid scintillation spectrometer. Protein contents
were determined by the biuret reaction, after precipitating
the samples with HClO4 and redissolved in NaOH. NOS-
specific activities were calculated in picomole citrulline
formed per minute per milligram protein units.
For the determination of hypothalamic tissue prostanoid
levels (prostaglandin D2, E2 and F2α, as well as the stable
prostacyclin and thromboxane A2 metabolites 6-keto-prosta-
glandin F1α and thromboxane B2, respectively), two groups of
animals, pretreated with the same protocol as described
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Hypothalamic tissue samples were frozen rapidly and kept at
−75 °C until further analysis. In order to measure prostanoid
concentrations, the hypothalamus was homogenized in 4
volumes of water (weight/volume) with an UltraTurrax and
afterwards with a glass potter. Deuterated internal standards
were added and prostanoids were extracted with 1 ml ethyl
acetate/hexane (7:3, v/v) as described (Schweer et al., 1994).
The sample was evaporated and reconstituted in 1 ml water.
Further derivatization and gas chromatography/triple quad-
rupole mass spectrometry (GC/MS/MS) conditions were
described previously (Schweer et al., 1994).
For the determination of COX mRNA expression by RT-
PCR, total RNA was isolated from hypothalamic tissue
samples by SV Total RNA Isolation System (Promega,
Madison, WI, USA). We used the same primer sets to detect
COX-1, COX-2 and β-actin mRNA as previously described
(Kis et al., 2003). For COX-3 detection, the sense primer
(5′-CAGAGTCATGAGTCGTGAG; 1376773–1376791 bases of
GenBank NW_047653.1) was designed to bind to intron 1
and the antisense (5′-AGAGGGCAGAATGCGAGTAT; 501–520
bases of GenBank S67721) to bind to exon 5 of the rat COX-1
gene, as previously described (Kis et al., 2004). The expected
length of the RT-PCR product was 573 base pairs. Our COX-3
primer set distinguishes between COX-1 and COX-3 and also
distinguishes between COX-3 and “partial” COXs (PCOX-1a,
PCOX-1b) because our antisense primer binds to exon 5
which is lacking in PCOXs (Chandrasekharan et al., 2002).
The conditions of the PCR reactions were set according to
the instructions of the Qiagen OneStep RT-PCR Kit. Briefly,
the RT reaction was performed at 50 °C for 30 min, followed
by the initial PCR activation step at 95 °C for 15 min. Thirty-
seven PCR cycles were performed with the following
parameters: denaturation 30 s at 94 °C, annealing 45 s at
58 °C and extension at 72 °C for 1 min. The last step of the
process was a final extension at 72 °C for 10 min. The COX
PCR products were identified by the size and the sequence.
Automated DNA sequencing of the PCR products was
performed on an ABI Prism 377 DNA sequencer (Applied
Biosystems, Foster City, CA, USA).
Western blotting method was described in details else-
where (Szabó et al., 2004). Briefly, the hypothalamic tissue
samples were prepared as described above and protein
content of the homogenate was determined by biuret reagent
and then the samples were heated in a buffer containing 10%
glycerol, 2.5% 2-mercaptoethanol, 5% SDS and 0.1% bromo-
phenol blue marker dye. After heat treatment, equal protein
amounts (70 μg in 10 μl) were applied onto the gel. After the
electrophoretic separation, samples were transferred to
nitrocellulose membranes. Samples were then blocked with
3% BSA for 24 h at 4 °C and tested for COX-1 and COX-2
isoenzymes using primary antibodies (Cayman, Ann Arbor,
MI, USA, 120 min, room temperature, 1:500 dilution). Anti-
rabbit horseradish peroxidase-conjugated secondary antibo-
dies (Sigma, 1:2000 dilution) were then added for 30 min and
finally membranes were treated with enhanced chemilumi-
nescence solution (Amersham, Buckinghamshire, UK) to
develop chemiluminescent bands that were visualized on
an X-ray film (Medifort, Forte, Vác, Hungary). Bands were
converted to computer-edited files. Positive controls wereused for both isoenzymes and molecular mass standard was
also run.
In order to measure the urinary excretion of prostacyclin
and prostaglandin E2 metabolites, the animals were housed
individually in metabolic cages (Techniplast, Buguggiate,
Italy). Urine samples were collected daily from control and
L-NAME-treated animals. The concentration of urinary
prostacyclin metabolites (2,3-dinor-6-keto-prostaglandin F1α
and 6-keto-prostaglandin F1α) was determined by a com-
mercial enzyme immunoassay kit (Assay Designs Inc., Ann
Arbor, MI, USA). The concentration of the urinary PGE2
metabolite 11α-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-
carboxyprostanoic acid was measured by GC/MS/MS as
described previously (Schweer et al., 1994). Urinary prosta-
noid concentrations were normalized with the concentration
of creatinine, which was measured by the Metra creatinine
assay kit (Quidel, San Diego, CA, USA).
L-NAME (Sigma), indomethacin (Merck) and diclofenac
(Sigma) were given in intravenous doses of 50, 5 and 10 mg/
kg, respectively, dissolved in 2 ml/kg saline. Intravenous
L-arginine (Sigma, dissolved in saline) administration con-
sisted of a 30 mg/kg initial bolus followed by 10 mg/kg/min
infusion with a rate of 0.1 ml/min.
All values are presented as mean±SEM; n represents the
number of animals. Statistical analysis was performed using
ANOVA for repeated measurements or one-way ANOVA
followed by Tukey's post hoc test. For comparison of two
groups, Student's unpaired t-test was used. A p value of less
than 0.05 was considered to be statistically significant.Acknowledgments
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Heme-oxygenase (HO)-derived carbon monoxide (CO) is gener-
ated in the cardiovascular and in the central nervous systems. En-
dogenous CO exerts direct vascular e¡ects and has also been
shown to inhibit nitric oxide synthase (NOS). In the current study,
the heme-oxygenase blockade [zinc deuteroporphyrin 2,4-bis gly-
col (ZnDPBG), 45mmol/kg intraperitoneally] decreased cerebral
CO production and increased cerebrocortical blood £ow (CBF)
in anesthetized rats.This latter e¡ect was abrogated by the NOS
blockade (50mg/kg L-NAME intravenously). Furthermore, inhibi-
tion of CO production had no e¡ect on stepwise hypoxia/hyper-
capnia-stimulated increases in CBF. Our results indicate that
endogenous CO reduces the resting CBF via inhibition of NOS
but fails to in£uence the CBF response to hypoxia and hyper-
capnia in adult rats. NeuroReport 18:1193^1197 c 2007 Lippincott
Williams &Wilkins.
Keywords: carbonmonoxide, cerebral circulation, heme oxygenase, hypercapnia, hypoxia, nitric oxide synthase
Introduction
Heme oxygenase (HO) catalyzes the degradation of mono-
meric free heme to generate carbon monoxide (CO) [1–4].
Previously thought to be simply a waste product, endogen-
ously formed CO is now known to serve as a messenger in
numerous physiological and pathophysiological processes
[1–4]. In the cardiovascular system, CO is an activator of
soluble guanylate cyclase and can promote the relaxation of
vascular smooth muscle, activate large-conductance cal-
cium-activated K+ channels and inhibit vascular smooth
muscle cell proliferation [4]. In the central nervous system,
CO plays an important role in synaptic plasticity, learning
and memory processes, as well as in the regulation of
hypothalamic neuropeptide release [1].
Expression of HO isoenzymes in neural and vascular
tissues is well documented [5,6]. It is also known that
freshly isolated cerebral microvessels, as well as micro-
vascular endothelial cells, produce CO. The generation of
CO is increased by stimulation of the ionotropic glutamate
receptors [6,7]. The role of endogenous CO, however, in the
regulation of the adult cerebral circulation is not well
understood [3]. In newborn pigs, both exogenous CO and
the HO substrate, heme, induce pial arterial dilatation; and
the latter can be inhibited by the HO blocker chromium
mesoporphyrin (CrMP) [5]. In addition, hypoxia-induced
vasodilation decreases, whereas hypocapnia-induced vaso-
constriction increases after topical application of CrMP [5,8].
Interestingly, pial arteriolar dilation in response to hyper-
capnia remains unaltered after topical CrMP treatment [5],
but gets reduced after systemic administration of another
HO inhibitor: tin protoporphyrin [9]. Cerebrospinal fluid
(CSF) levels of endogenous CO increase during seizures
[9,10], and seizure-induced pial arteriolar dilatation and the
cerebral blood-flow increase are attenuated by HO inhibi-
tors in piglets and adult male rats, respectively [10–12].
Glutamate receptor-mediated dilation of newborn pig pial
arterioles also involves the HO pathway [7,13]. It appears
that endogenous CO dilates piglet cerebral arterioles by
augmenting the coupling of Ca2+ sparks to KCa channels
in smooth muscle cells [14].
Although the majority of the cerebrovascular studies have
been carried out in newborn models, cerebral vasoregulatory
mechanisms are known to change substantially during
maturation. Furthermore, recent studies confirm that CO-
synthesizing and nitric oxide-synthesizing enzymes are
colocalized in cerebral vessels and perivascular neuronal cells
[6,15]. As CO has been shown to inhibit nitric oxide synthase
(NOS) activity [16], it raises the possibility of interactions
between these pathways in cerebral circulation. We, therefore,
wanted to determine the influence of the HO pathway on the
cerebrocortical blood flow (CBF) in adult animals in the
presence and absence of a functional NOS system, under
resting and combined hypoxic/hypercapnic conditions.
Materials and methods
Experiments were performed using adult male Wistar
rats (body weight 300–400 g), under the guidelines of the
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Hungarian Law of Animal Protection (243/1988), and with
approval from Semmelweis University Committee on
Ethical Use of Experimental Animals (590/99 Rh). During
the in-vivo experiments, the animals were anesthetized with
urethane (1.3 g/kg intraperitoneally, Sigma), while sponta-
neously breathing via a fitted trachea cannula. Indwelling
catheters were inserted into the right femoral artery for
blood pressure measurements and sampling and into the
left femoral vein for drug administration. Femoral arterial
blood gases (PaCO2, PaO2, O2 saturation) and acid–base
parameters (pH, standard base excess) were measured with
an ABL-300 Radiometer Blood Gas Analyzer (Brnshj,
Denmark). CBF was measured with a two-channel laser-
Doppler (LD) monitor (MBF 3D, Moor Instruments, Devon,
UK) as described previously [17], with infrared laser light
(780 nm) penetrating 1mm into the brain, spanning 7mm2
of parietal cortex.
In the first part of the study, the effect of HO blockade
on the CBF was studied under physiological (normoxic/
normocapnic) conditions. The first experimental group
served as a vehicle-treated control and CBF was determined
before and after an intraperitoneal injection of 3ml saline.
In the second group, ZnDPBG [zinc deuteroporphyrin
2,4-bis glycol, Frontier Scientific (Logan, Utah, USA),
45mmol/kg intraperitoneally] was applied. This had
previously been shown to effectively inhibit HO activity
in the rat brain [18]. Animals in the third and fourth
experimental groups were pretreated with the NOS
inhibitor L-NAME (NG-nitro-L-arginine methyl ester, Sigma,
50mg/kg intravenously). Thirty minutes later the third and
fourth groups received saline or ZnDPBG, respectively. CBF
was determined in all experimental groups before as well as
15, 30 and 45min after the administration of vehicle or
ZnDPBG.
To verify the inhibitory effect of ZnDPBG on brain HO
activity in vivo, matched series of animals were treated with
either ZnDPBG or vehicle as described above. Thirty
minutes later, innate cerebral CO generation was deter-
mined using solid-phase gas chromatography (custom built
Peak Performer 1 RCP; Peak Laboratories LLC, Mountain
View, California, USA) as described in detail elsewhere
[8,19]. Briefly, isolated midbrain tissues from each animal
were individually sonicated in Krebs’ buffer and divided
into eight aliquots. For each animal midbrain sample, head
space CO was measured in quadruplicate vials after being
maintained at 21C or the remaining matched aliquots after
being incubated at 371C for 60min. The differences between
the incubated and cold vials were expressed as mmol CO
generated/kg of wet tissue per hour. ZnDPBG induced
a reduction of cerebral HO activity from 4.5870.87 to
2.4770.36 mmol/kg per hour (P¼ 0.025).
In the second part of the study, the effect of HO blockade
on the cerebrocortical hyperemic response to hypoxia/
hypercapnia (H/H) was examined. H/H was induced in a
stepwise manner by the administration of different gas
mixtures (5%O2–20%CO2–75%N2 for producing moderate
H/H and 20%CO2–80%N2 for producing severe H/H,
respectively) with a constant flow of 3 l/min through a
5ml chamber connected to the trachea, at atmospheric
pressure. CBF was recorded continuously and peak CBF
values were determined during the two 10-min long steps of
H/H. After the first moderate and severe H/H challenge,
the animals were divided into two experimental groups
receiving either saline or ZnDPBG intraperitoneally. Thirty
minutes later the moderate and severe H/H was repeated in
both groups and peak CBF values were determined from the
continuous recording of CBF.
The in-vitro experiments were performed in the middle
cerebral arteries (MCAs) supplying the parietal cortex, the
site of our in-vivo CBF measurements. MCA segments were
prepared from adult male Wistar rats as described pre-
viously [20] and studied in a conventional myograph system
(Danish Myo Technology A/S, Aarhus, Denmark). The
effects of 10mM ZnDPBG or 10mM bradykinin (as positive
control) were tested after precontraction of vessels by 10 mM
prostaglandin F2a.
Results
Effects of heme-oxygenase blockade under normoxic/
normocapnic conditions
Arterial blood gas and acid–base parameters were within
the physiological range (PaO2: 90–105mmHg, O2 saturation:
95–97%, PaCO2: 40–45mmHg, pH: 7.32–7.36, standard base
excess: 3–0mM) during the experiments. L-NAME pre-
treatment increased mean arterial blood pressure (from
102.273.0 to 146.374.1mmHg, Po0.001), decreased heart
rate (from 424712 to 373712 beats/min, P¼ 0.012) and
reduced CBF (from 359718 to 258713 AU, Po0.001).
Administration of ZnDPBG, which inhibits CO formation,
increased CBF, but saline vehicle alone had no effect (Fig. 1).
Inhibition of NO formation by L-NAME pretreatment
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completely blocked ZnDPBG-induced elevations of CBF
(Fig. 1). Under in-vitro conditions, 10mM ZnDPBG had no
effect on the tension of isolated MCA segments; this effect
cannot be attributed to endothelial damage as functionally
intact endothelium was confirmed by relaxation to 10mM
bradykinin (7975% of the precontraction induced by
prostaglandin F2a).
Effects of heme oxygenase blockade on the hypoxia and
hypercapnia induced increase of cerebrocortical blood
flow
Before the initial H/H challenge, baseline cardiovascular,
arterial blood gas and acid–base parameters were within
physiological ranges in both (later ZnDPBG-treated or
saline-treated) experimental groups. During moderate
H/H, PaO2 was reduced to 60–65mmHg, PaCO2 was
increased to 80–85mmHg and pH decreased to 7.10–7.15
(Fig. 2a). Despite no change in MAP, CBF increased in both
experimental groups by B45% (Fig. 2b). During severe
H/H, PaO2 was reduced to 45–50mmHg, PaCO2 was
increased to 95–100mmHg and pH decreased to 7.05–7.10
(Fig. 2a); CBF increased in both experimental groups by
B65% (Fig. 2c), whereas MAP remained unchanged.
The second stepwise H/H challenge, after ZnDPBG or
saline, induced similar changes in the blood-gas tensions
and pH as the initial challenge had done (Fig. 2a), without
affecting MAP (data not shown). Most important, neither
ZnDPBG nor saline treatment had any effect on CBF
responses to moderate (Fig. 2b) or severe (Fig. 2c) H/H,
when compared with the pretreatment values.
Discussion
Our current study provides evidence for the interaction
between the HO and NOS pathways in the regulation of the
CBF that had been described in the other vascular beds
[19,21,22]. The CBF increase after administration of ZnDPBG
and its inhibition with L-NAME pretreatment indicate
that constitutive CO release tonically suppresses the NO
production and consequently reduces blood flow in the
cerebral cortex.
The interactions between CO and NO are well documen-
ted. Endogenous CO is known to relax smooth muscle, but
in the presence of a functional endothelium CO-induced
inhibition of NOS can promote vasoconstriction [4,21].
Systemic inhibition of CO formation, with CrMP, has no
effect on hindlimb vascular resistance but promotes a
marked and sustained vasoconstriction after L-NAME
pretreatment [19]. Delta-aminolevulinic acid, a heme pre-
cursor that promotes CO formation, causes vasoconstriction
in intact isolated rat gracilis muscle arterioles, but
is converted to vasodilation by removal of the endo-
thelium and by pretreatment with L-NAME to inhibit
NO formation [22]. These earlier studies provide evidence
that CO-induced constriction arises from the suppression
of endothelial NO production. Furthermore, L-NAME
increased the reduction of renal blood flow and augmented
the contraction of isolated renal interlobular arteries
in response to the HO inhibitor stannous mesoporphyrin
[23].
It has been suggested that HO-derived CO can be a
primary regulator of NO production [16], and a growing
body of evidence continues to support that contention.
Ishikawa et al. [15] have demonstrated that HO-2 is
colocalized with endothelial NOS (eNOS) in the cerebro-
vascular endothelium as well as with neuronal NOS (nNOS)
in neurons and arachnoid trabecular cells, suggesting that
the colocalization of the CO-generating and NO-generating
pathways are sufficient for interaction. Tricarbonyldichloro-
ruthenium (II) dimer, a CO-releasing molecule, was shown
to reduce NO release from cultured endothelial cells. In
addition, HO blockade by zinc protoporphyrin IX (ZnPP)
induced CO-reversible and L-NAME-reversible increase of
the cerebrovascular and perivascular NO production by
70–80%. These results are comparable with the ZnDPBG-
induced 67% increase of the NOS activity in the rat
hypothalamus observed in our previous study [24]. Most
important, ZnPP induced a dose-dependent increase of
the pial arteriolar diameter, which could be prevented
by coadministration of either CO or L-NAME, indicating the
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involvement of NO in the mediation of the vasodilation.
Our current results confirm and complement these observa-
tions by providing direct evidence for the significance of the
CO–NOS interaction at the level of cerebrocortical blood
perfusion. In our study, however, ZnDPBG failed to relax
the isolated middle cerebral artery, whereas Ishikawa et al.
[15] reported marked pial arteriolar dilatation in response to
ZnPP in rats. As, in the latter study, pial arteriolar responses
were determined in vivo, the most plausible explanation of
the discrepancy between the two findings is that reduction
of nonvascular CO release or augmentation of nonvascular
NO release plays an important role in CBF increase after
inhibition of HO.
As HO degrades heme to form CO, iron and biliverdin,
alternative interactions might explain the influence of
HO activity on cerebrovascular NO functions [25]. It has
been described that CO binds directly to NOS and inhibits
NO production. Iron released in the course of heme
degradation by HO can inhibit de-novo NOS synthesis by
inhibiting its nuclear transcription, but our currently
reported effect is rapid and is, therefore, unlikely to arise
from changes in protein synthesis. Alternatively, HO
activity might influence NOS synthesis by changing heme
availability and the active site of NOS requires two heme
molecules. Finally, the NOS and HO pathways might
interact by competing for NADPH as a cofactor required
for their enzymatic activity. It has, however, been shown
that exogenous CO promotes vasoconstriction and mimics
the effects of increased HO activity, suggesting a nico-
tinamide adenine dinucleotide phosphate-independent
mechanism [22].
Our current study also shows that the HO–CO pathway
does not play a discernible role in hypoxia/hypercapnia-
induced increased CBF in adult rats. This observation is
different from that of previous studies in newborn models
in which HO blockade inhibited the pial arteriolar dilation
in response to hypoxia or hypercapnia [5,9]. As the
regulatory processes of the CBF during hypoxia or
hypercapnia show marked alterations during maturation,
we can only speculate that our contrasting findings arise
from age-related differences in the models. Furthermore, we
cannot exclude the possibility that endogenous CO can have
dual cerebrovascular effects during H/H: (i) it directly
facilitates the H/H induced CBF increase, but (ii) its
simultaneous inhibitory influence on NO synthesis neutra-
lizes this effect. Further studies can clarify this hypothesis
and investigate the role of endogenous CO in the adaptation
of the cerebral circulation to chronic hypoxia when the
expression of HO-1 is increased in the brain [2].
Conclusions
Our results indicate that endogenous CO exerts a tonic
influence on resting CBF by inhibiting NO synthesis.
Furthermore, inhibition of the HO–CO pathway increases
CBF most likely by increasing neuronal NO production.
Finally, the HO–CO pathway does not influence hypoxia
and hypercapnia-induced CBF increase in adult rats.
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The heme oxygenase (HO)^ carbon monoxide pathway was ear-
lier shown to increase hypothalamic blood £ow after inhibition of
nitric oxide synthesis in rats.We hypothesized that this e¡ect is
mediated by prostaglandin E2 (PGE2). Inhibition of constitutive
HO activity decreased cerebral PGE2 production and simulta-
neously increased hypothalamic nitric oxide synthase (NOS) activ-
ity without changing hypothalamic blood £ow. Furthermore,
HO blockade induced cyclooxygenase-dependent decrease and
NOS-mediated increase of the hypothalamic blood £ow after
inhibition of NOS and cyclooxygenase, respectively. Therefore,
constitutive carbon monoxide release seems to have two indirect
e¡ects on the hypothalamic circulation: vasodilation mediated
by PGE2 and vasoconstriction as a result of NOS inhibition.
NeuroReport 19:1601^1604 c 2008 Wolters Kluwer Health |
LippincottWilliams &Wilkins.
Keywords: carbonmonoxide, cerebral circulation, cyclooxygenase, heme oxygenase, hypothalamus, nitric oxide synthase, prostaglandin E2
Introduction
Carbon monoxide (CO) produced by heme oxygenase (HO)
enzymes has been recently recognized as an important
mediator in numerous physiological and pathophysiological
processes. In the central nervous system, CO plays an
important role in synaptic plasticity, learning and memory
processes, thermal regulation and modulation of hypotha-
lamic neuropeptide release [1,2]. Furthermore, the HO
pathway has been recently implicated as one of the main
regulatory components of the cerebral circulation [3,4].
Most of the experimental data regarding the cerebro-
vascular functions of endogenous CO has been obtained in
newborn or juvenile pigs [4]. It has been shown that CO
dilates piglet cerebral arterioles by enhancing the coupling
of Ca2 + sparks to KCa2 + channels in smooth muscle cells.
Glutamate activates the HO pathway in cerebral vessels and
astrocytes and endogenous CO mediates glutamate and
seizure-induced pial arteriolar dilation in newborn pigs.
Furthermore, endogenous CO contributes to the cerebral
vasodilation in response to hypoxia and hypotension [4].
The role of endogenous CO in the adult cerebral circu-
lation is far less understood, although a recent study indi-
cated that the cerebrovascular effects of the HO pathway
might substantially change with age [5]. In adult rats, the
cerebrovascular responses to seizures and to the ionotropic
glutamate receptor agonist alpha-amino-3-hydroxy-5-methyl-
isoxazole-4-propionic acid are also mediated, at least in part,
by endogenous CO [6,7]. The effects of hypoxia and
hypercapnia on the cerebrocortical circulation are, however,
independent of the HO pathway [6,8]. Interestingly, the
inhibition of constitutive HO activity results in nitric oxide
(NO)-mediated pial arteriolar dilation and cerebrocortical
hyperemia both in newborn pigs and in adult rats [8–10]
indicating that endogenous CO tonically suppresses
NO-mediated cerebrocortical vasodilation. In a recent study,
we have observed this indirect vasoconstrictor effect of the
HO pathway also in the rat hypothalamic circulation but
it was compensated by a simultaneous vasodilator action of
CO through a yet unidentified mechanism [11]. In this study,
we hypothesized that prostaglandin E2 (PGE2) mediates
the vasodilatory effect of constitutive HO activity on the
hypothalamic blood flow of adult rats. Although vasodilator
prostanoids are not involved in the mediation of CO-induced
cerebrovascular responses in newborn pigs, [4] in a recent
study endogenous CO was shown to stimulate the release of
PGE2 from hypothalamic tissue explants of adult rats [12].
Our first aim was to investigate the presence of this
interaction in vivo by measurement of prostanoid levels in
the cerebrospinal fluid after inhibition of constitutive HO
activity. Furthermore, we aimed to evaluate the significance
of the HO–PGE2 interaction in the regulation of the resting
hypothalamic blood flow.
Methods
The experiments were carried out in adult (300–400 g body
weight) male Wistar rats anesthetized with 1.3 g/kg
intraperitoneally (i.p.) injected urethane, and spontaneously
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breathing through a trachea cannula. Catheters were inser-
ted into both femoral arteries (for systemic arterial blood
pressure measurement and for blood sampling) and into
the left femoral vein (for drug administration). The skull
was fixed in a stereotaxic head-holder. Body temperature
was kept constant between 36 and 381C with a controlled
heating lamp.
Systemic arterial pressure was recorded continuously on a
polygraph (Model 7E, Grass, Quincy, Massachusetts, USA).
Hypothalamic blood flow was determined by using Auk-
land’s H2-gas clearance method as described elsewhere [13].
Briefly, a teflon-coated platinum electrode of 100 mm
diameter with a 1 mm bare tip was introduced stereotacti-
cally into the ventromedial hypothalamic area. H2-wash-out
curves were produced by H2-gas inhalation, and were
recorded on the polygraph. Tissue blood flow was calcu-
lated from the washout curves by using the initial slope
technique, omitting the first 0.5 min. Blood gas values
(PaCO2, PaO2, O2 saturation) and pH were measured in
femoral arterial samples by a Radiometer Blood Gas
Analyzer (ABL-300, Copenhagen, Denmark) at the times
of blood flow determinations. Mean arterial blood pressure
and heart rate were also determined at the same time points.
After the last measurements, the anesthetized animals were
rapidly exsanguinated and hypothalamic tissue samples
were excised, frozen rapidly, and kept at –751C until the
measurement of NOS activity on the basis of labeled
citrulline formation from labeled L-arginine as described
[11]. Briefly, tissue samples were homogenized in brain
homogenizing solution containing 50 mM TrisHCl (pH 7.4),
0.3 M sucrose, 0.1 mM EDTA, 1 mM dithioerythritol, and
1 mM phenyl-methyl-sulfonylfluoride (protease inhibitor).
Homogenates were added to the samples containing 5 mM
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, 1 mM
nicotinamide adenine dinucleotide phosphate, 10 mM tetra-
hydrobiopterin, 30 mM calmodulin, 2.5 mM CaCl2 at 7.4 pH
and reaction was initiated by adding 20 mM 3H-arginine
(final concentrations). After 30 min incubation, the reaction
was stopped and samples were put onto 2 cm Dowex-50 8
resin columns. Eluates were mixed with 5 ml dioxane-based
scintillation fluid and measured in a Beckman liquid scintil-
lation spectrometer (Palo Alto, California, USA). Protein
contents were determined by the biuret reaction, and NOS
activities were calculated in pmole citrulline formed per
minute per milligram protein units.
To determine the effect of HO blockade on cerebral
prostanoid production, two groups of animals were anes-
thetized as described above and treated i.p. with either
the HO inhibitor zinc deuteroporphyrin 2,4-bis glycol
(ZnDPBG, 45 mmol/kg i.p.) or saline. Forty-five minutes
later, cerebrospinal fluid was obtained from the cisterna
magna and kept at 751C until further analysis. Concen-
trations of prostaglandin (PG) D2, E2, and F2a, as well as
the stable prostacyclin metabolite 6-keto-PGF1a have been
determined using gas chromatography/triple quadrupole
mass spectrometry as described previously [14].
All chemicals were obtained from Sigma (St Louis,
Missouri, USA) except for ZnDPBG, which was purchased
from Frontier Scientific Europe Ltd (Carnforth, Lancashire,
UK). Earlier studies have verified that diclofenac, ZnDPBG,
and NG-nitro-L-arginine methyl ester in the doses
used in this study are effective in the brain for inhibition
of cyclooxygenase (COX), HO, and NOS, respectively
[8,15,16].
All values are presented as mean7SEM; n represents the
number of animals. Statistical analysis was performed using
analysis of variance for repeated measurements or one-way
analysis of variance followed by Dunnett’s post-hoc test. For
comparison of two groups, Student’s unpaired t-test was
used. A P value of less than 0.05 was considered to be
statistically significant.
Results
Inhibition of the HO pathway by ZnDPBG (45 mmol/kg i.p.)
resulted in decreased concentrations of PGE2 in the
cerebrospinal fluid without influencing the levels of other
prostanoids such as PGD2, 6-keto-PGF1a, and PGF2a (Fig. 1).
Thereafter, the effect of ZnDPBG on the hypothalamic blood
flow has been determined in two groups of animals with
normal PGE2-synthesizing capacity or after the inhibition of
COX enzymes by diclofenac (10 mg/kg intravenously).
ZnDPBG had no effect in control animals but significantly
increased hypothalamic blood flow after diclofenac (Fig. 2a)
without influencing arterial blood gas, acid–base, or
systemic circulatory parameters (data not shown). After
diclofenac pretreatment, the ZnDPBG-treated rats showed
significantly (P¼0.007) higher hypothalamic NOS activity
(5.3071.05 pmol citrulline/mg protein/min) as compared
with saline-treated controls (2.4570.32 pmol citrulline/mg
protein/min). In animals pretreated by both diclofenac
and the NOS inhibitor, NG-nitro-L-arginine methyl ester
(50 mg/kg intravenously) and ZnDPBG failed to influence
the hypothalamic blood flow (Figure 2a).
Discussion
In contrast to the well-documented role of NO in the
cardiovascular system [17], the vascular actions of endo-
genous CO are poorly understood. Results of this study
coupled with our earlier observations, indicate that the
resting activity of the HO pathway has a dual influence on
the hypothalamic circulation; a vasodilation mediated by
PGE2 and a simultaneous vasoconstriction owing to the
reduction of NO synthesis. Under resting conditions these
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two effects are equally potent and neutralize each other, at
least in the hypothalamus. In the cerebral cortex, however,
the NO-mediated pathway seems to be dominant and HO
blockade results in a NO-mediated pial vasodilation [9,10]
and cerebrocortical hyperemia [8]. These observations
support the view that the HO pathway has a regionally
heterogeneous influence on the cerebral circulation through
interaction with the NOS pathway.
The most important new finding of this study is that the
vasodilator influence of the HO pathway on the hypotha-
lamic vasculature is mediated by PGE2. HO cleaves heme
moieties liberating equimolar amounts of CO, free iron, and
biliverdin, which are converted to bilirubin by biliverdin
reductase. From these metabolites, CO and biliverdin are the
putative regulators of PGE2 synthesis, as they have been
shown to stimulate the release of PGE2 from primary
cultures of rat hypothalamic cells in vitro [12,18]. These
observations and a recent report indicating that the HO
pathway has no direct influence on the PGE2 synthesis
in cerebral microvessels [19] clearly suggest that brain
parenchymal rather than vascular PGE2 release mediates
the vasorelaxant effect of constitutive HO. This would also
explain why exogenous CO reportedly relaxes rat pial
arteries only under in-vivo conditions [5], but not in vitro
[20]. Stimulation of neuronal PGE2 release by the HO
pathway, however, may also be involved in physiological
functions other than regulation of the hypothalamic blood
flow. It has been recently proposed that this interaction may
have physiological relevance in thermal regulation and
modulation of hypothalamic neuropeptide release [2].
In an earlier study, we have described an indirect
influence of the HO pathway on the hypothalamic circula-
tion through inhibition of NO synthesis [11]. Experimental
data of this earlier study together with the present
observations are summarized in Fig. 2b, indicating that
HO blockade by ZnDPBG has no influence on the hypo-
thalamic blood flow under resting conditions but results in
either a decreased or an increased blood flow after NOS-
blockade and COX-blockade, respectively. After simulta-
neous NOS-blockade and COX-blockade, ZnDPBG fails to
influence the hypothalamic circulation. The proposed path-
ways mediating the effects of HO metabolites on the
hypothalamic vasculature are depicted in Fig. 2c. Although
the HO pathway seems to have no direct cerebrovascular
effect in adult rats, it can both increase and decrease
hypothalamic blood flow through stimulation of PGE2
release or inhibition of NO release, respectively. Under
physiological conditions these pathways are equally potent
and neutralize each other. In case of diminished NO
production, however, the PGE2 pathway may dominate
and contribute to the maintenance of the hypothalamic
blood supply. It is noteworthy that this pathway seems to be
independent from the morphological or functional integrity
of the endothelium, as CO can be produced by vascular
smooth muscle and brain parenchymal cells [21,22] and the
secondary PGE2 release also seems to originate from
nonvascular cells (as mentioned above). Therefore, the
HO–CO–PGE2–cAMP pathway is an ideal ‘backup’ med-
iator for maintaining the hypothalamic blood perfusion
in case of insufficient endothelial NO production, for
example in atherosclerosis or hemorrhagic shock. Under
these pathophysiological conditions, stimulation of endo-
genous CO production or administration of CO-releasing
substances may have a potential therapeutic value by
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cle, n¼5), or combined nitric oxide synthase (NOS) and COX blockade
(triangles, n¼7) before (0min) as well as15, 30, and 45min after the admin-
istration of the heme oxygenase (HO) inhibitor zinc deuteroporphyrin 2,4-
bis glycol (ZnDPBG).Values aremean7SEM. *Po0.05 and **Po0.01versus
‘0min’. (b) Changes in hypothalamic blood £ow after administration of the
HO inhibitor ZnDPBG in animals pretreated with vehicle (open bar),
the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (vertically
stripped bar), the COX inhibitor diclofenac (horizontally stripped bar), and
combination of L-NAME and diclofenac (¢lled bar).Values are mean7SEM.
*Po0.05 versus ‘saline’. (c) Proposed mechanism of the dual action of HO
on the hypothalamic circulation.
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preventing hypothalamic ischemia and the consequent
disturbances of homeostatic functions.
In case of sustained induction of HO activity, however, the
above-described interaction between the HO and COX
pathways can be changed substantially. As COX enzymes
are heme proteins and the heme prosthetic group is essential
for their catalytic activity, heme degradation by HO may
negatively influence COX activity. In accordance, HO-1
induction has been shown to reduce COX expression and
activity in endothelial cells [23] and in the kidney [24].
Furthermore, HO-1 induction in the endothelium results in
increased expression of PG transporter and in enhanced PG
clearance [25]. This study indicates that the constitutive HO
activity in the brain fails to induce such effects as the PGE2
levels decrease after HO blockade whereas other prosta-
noids remain unaltered. In pathophysiological states asso-
ciated with HO-1 induction in the brain (e.g. subarachnoid
hemorrhage), however, the decreased production and
enhanced clearance of PGE2 and PGI2 together with the
CO-mediated inhibition of NOS activity [9,11] may nega-
tively influence the cerebral circulation.
Conclusion
This study identifies PGE2 as the primary mediator of the
vasodilator influence by constitutive HO activity on the
hypothalamic circulation in adult rats. Under physiological
conditions this effect of CO is counterbalanced by the
suppression of NOS. The HO pathway seems to regulate
the cerebral circulation of adult rats mainly through
interactions with the COX and NOS pathways in a
regionally heterogeneous manner.
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Additive effect of cyclooxygenase and nitric oxide synthase
blockade on the cerebrocortical microcirculation
Zsombor Lacza, La´szlo´ Hortoba´gyi, Be´la Horva´th, Eszter M. Horva´th,
Pe´ter Sa´ndor and Zolta´n Benyo´
The contribution of vasodilator cyclooxygenase (COX)
metabolites to the maintenance of the cerebrocortical
blood flow (CBF) has been studied under physiological
conditions and in nitric oxide (NO) deficiency. Inhibition
of COX decreased resting CBF without changing
arterial blood pressure. NO synthase blockade resulted
in hypertension and CBF reduction as well as in enhanced
cerebral prostacyclin and prostaglandin E2 production.
Despite the increased vasodilator prostanoid release
in the absence of NO, the CBF-decreasing effect of COX
blockade failed to increase. Therefore, the COX pathway
seems to play a similar role under physiological and
NO-deficient conditions in the maintenance of the resting
CBF. NeuroReport 20:1027–1031 c 2009 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
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Introduction
Cyclooxygenase (COX) inhibitors are the most widely
used pharmaceutical agents worldwide. Unfortunately,
apart from their beneficial anti-inflammatory, antipyretic
and analgesic effects, COX inhibitors can produce side
effects, particularly in the gastrointestinal and cardio-
vascular systems [1]. While gastrointestinal complications
are mainly attributed to the inhibition of the COX-1
enzyme, it is believed that adverse cardiovascular effects
(e.g. increased risk of myocardial infarction and stroke)
are mainly the consequences of COX-2 blockade and
related to the decreased synthesis of vasodilator and
antithrombotic prostanoids, such as prostacyclin (PGI2)
and prostaglandin E2 (PGE2). In a healthy vasculature,
the effects of COX blockade may be less deleterious in
the presence of the potent vasodilator and antithrom-
botic action of endothelium-derived nitric oxide (NO).
The release and/or biological half-life of NO, however, can
be severely diminished in certain pathophysiological
states including arteriosclerosis, diabetes or hyper-
homocysteinemia [2]. In NO deficiency, the release and
functional importance of vasodilator prostanoids may
substantially increase and therefore COX inhibition may
result in enhanced cardiovascular complications. For
instance, recent reports from our and several other
laboratories indicated that vasodilator prostanoids, mainly
PGI2 and PGE2, play an important compensatory role in
the absence of NO in the coronary circulation, and COX
blockade aggravates the reduction of coronary blood
flow induced by inhibition of the NO synthesis [3–5].
A similar interaction between the NOS and COX
pathways in the cerebral circulation is far less studied
although it may explain the increased risk of cerebro-
vascular complications induced by COX inhibitors in
diseases associated with decreased availability of NO,
such as diabetes or arteriosclerosis [2].
Although the initial intracellular signaling steps of
NO-induced and prostanoid-induced smooth muscle
relaxation are substantially different (i.e. direct stimula-
tion of guanylyl cyclase and Gs protein coupled receptor
mediated activation of adenylyl cyclase, respectively), the
prostanoid system can very effectively compensate
for the loss of the NO–cGMP pathway [6]. For instance,
although cGMP seems to selectively activate protein
kinase G (PKG), cAMP activates both protein kinase A
(PKA) and PKG. Furthermore, most of the molecular
targets of PKG can also be phosphorylated by PKA and
the adenylyl cyclase–cAMP–PKA pathway is upregulated
in the absence of NO [6]. Therefore, in this study we
hypothesized that PGI2 and/or PGE2 may have an
accentuated role in the maintenance of the cerebral
blood flow in NO deficiency. To test this hypothesis we
examined whether (i) inhibition of NO synthesis results
in enhanced cerebral PGI2/PGE2 release and (ii) NO
deficiency potentiates the cerebral blood flow changes
induced by COX blockade in rats. We performed blood
flow measurements in the cerebral cortex, because in a
previous study the blood perfusion of this brain region
was relatively well preserved after NO synthase (NOS)
blockade [7] indicating the presence of effective
compensatory mechanism(s).
0959-4965 c 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins DOI: 10.1097/WNR.0b013e32832d6a93
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Methods
The experiments were performed on 46 adult male
Wistar rats (body weight 300–400 g) under the guidelines
of the Hungarian Law of Animal Protection (243/1988)
and all procedures were approved by the Semmelweis
University Committee on the Ethical Use of Experi-
mental Animals (590/99 Rh). The animals were anesthe-
tized with urethane administered intraperitoneally
(1.5 g/kg; Sigma), the depth of anesthesia was regularly
controlled during the experiments by checking the
corneal or plantar nociception reflex and additional
urethane was administered intravenously (i.v.) as neces-
sary. The right femoral vein was cannulated for
drug administration and the right femoral artery for the
measurement of mean arterial blood pressure and to
allow sampling for analysis of arterial blood gases.
The animals were artificially ventilated through an intra-
tracheal cannula with a mixture of humidified air and
oxygen; blood gases were analyzed regularly and kept
in the physiological range. Core temperature of
the animals was kept at 371C with a heating blanket and
a thermostat.
The measurement of cerebrocortical blood flow (CBF)
was performed by laser-Doppler (LD) flowmetry as
described in detail elsewhere [8]. The head of the
animal was fixed in a stereotaxic head holder with the
nose 5mm down from the interaural line. The skull of
the parietal region was exposed and the bone was thinned
over the parietal cortex on both sides with a microdrill, so
that the lamina interna of the skull remained intact. Two
LD probes were placed above the thinned skull at a
121 angle to the vertical to provide an optimal view of
the cortex (4mm caudal from bregma, 5mm lateral from
midline). CBF was measured with a two-channel blood
flow monitor (MBF3D, Moor Instruments, UK) and was
recorded continuously. The LD monitor was calibrated
before each individual experiment with a constant
movement latex emulsion. The laser light was in the
infrared range (780 nm) and penetrated about 1mm into
the brain covering approximately 7mm2 of the parietal
region, so that the data acquired mostly represented the
characteristics of the parietal cortex [8].
Animals were randomly assigned to four in-vivo experi-
mental groups. In the first (control) group (n=5),
systemic and cerebral circulatory parameters, as well
as blood gas and acid–base values, were determined
both before and after 30min of an i.v. bolus injection of
1ml/kg vehicle (saline). The second group (n=10)
received i.v. NG-nitro-L-arginine methyl ester (L-NAME,
Sigma, St. Louis, Missouri, USA) at a dose of 50mg/kg
for the inhibition of NO synthesis and the measure-
ments were performed using the same protocol. In the
third group of rats (n=6), the effects of COX blockade
were determined (induced by 10mg/kg i.v. indomethacin,
Merck, Rahway, New Jersey, USA), whereas in the fourth
group (n=5) the combined effects of NOS and COX
inhibition were determined.
To analyze the effect of NOS blockade on the formation
of vasodilator prostanoids in the brain, two additional
groups of animals were anesthetized and treated either
with vehicle (n=11) or L-NAME (n=9) as described
above. Forty-five minutes later, cerebrospinal fluid (CSF)
was obtained from the cisterna magna and kept at – 751C
until further analysis. Concentrations of PGE2 and the
stable prostacyclin metabolite 6-keto-prostaglandin F1a were
determined using chemiluminescence enzyme immuno-
assay kits (Assay Designs, Ann Arbor, Michigan, USA).
All values are presented as mean±SEM; n represents
the number of experiments. Statistical analysis was per-
formed using analysis of variance followed by Newman–
Keuls post-hoc test. For comparison of two groups,
Student’s unpaired t-test was used. A P value of less
than 0.05 was considered to be statistically significant.
Results
Inhibition of NO synthesis resulted in increased levels
of PGE2 and PGI2 in the CSF (Fig. 1). At the beginning
of the in-vivo experiments, the arterial blood gas and
acid–base parameters were within the physiological
range (pCO2 36.9±0.6mmHg; pO2 106.3±2.8mmHg;
pH 7.37±0.01) and did not change during the measure-
ments in any of the experimental groups (data not
shown). NOS blockade induced marked hypertension and
at the same time significant reduction of the CBF
Fig. 1
700
Saline
∗∗∗∗∗∗L-NAME600
500
400
300
200
100
0
PGI2
C
SF
 p
ro
st
an
oi
d 
co
nt
en
t 
(p
g/
m
l)
PGE2
Prostanoid levels in the cerebrospinal fluid (CSF) after administration
of the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester
(L-NAME) (closed bar, n= 9), or its vehicle (open bar, n= 11). Values
are mean ± SEM. ***P< 0.001 vs. saline. PGE2, prostaglandin E2;
PGI2, prostacyclin.
1028 NeuroReport 2009, Vol 20 No 11
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
(Fig. 2). Inhibition of COX by indomethacin also
decreased CBF but had no influence on the blood
pressure (Fig. 2). Combined NOS and COX blockade
induced hypertension and more severe CBF reduction
than inhibition of any of these pathways alone (Fig. 2).
However, two-factor analysis of variance revealed
that there was no interaction (P=0.25) between
the cerebrovascular effects of the two interventions
indicating that NO deficiency did not enhance the
CBF-decreasing effect of COX blockade despite the
increased release of vasodilator prostanoids.
Discussion
The high vulnerability of central nervous system neurons
to hypoxia and the deleterious consequences of
ischemic neuronal damage with respect to the survival of
the organism require that very precise and effective
vasoregulatory mechanisms control the cerebral circula-
tion. Perhaps the most important vasoactive agent
involved in the maintenance of the proper blood supply
to the brain is NO, both under resting conditions and
during functional hyperemia. In NO deficiency, however,
other vasoactive mediators may substitute NO to
maintain sufficient blood perfusion of the brain. Recently,
endogenous CO was proposed to serve as a ‘backup’
vasodilator in the hypothalamus in the absence of NO
[9,10]. However, we have recently shown that in the
cerebral cortex CO functions as a vasoconstrictor [8] and
therefore it cannot compensate for the loss of NO.
Despite this fact, the cerebrocortical blood flow is
relatively well preserved in the absence of NO as
compared with other brain regions [7], which indicates
the presence of effective compensatory mechanisms.
Several lines of evidence indicate that vasodilator
prostanoids may be involved in the adaptation of
the circulatory system to NO deficiency. For instance,
the contractile effect of the COX inhibitor mefenamic
acid in rat diaphragmatic arterioles was enhanced
significantly after NOS blockade [11]. Furthermore, in
this experimental system, simultaneous administration
of mefenamic acid and the NOS inhibitor nitro-L-arginine
completely prevented the acetylcholine-induced vasodi-
lation, although these drugs were without any signifi-
cant effect when applied separately [11]. After the
inhibition of NOS, elevated plasma levels and increased
urinary excretion of PGI2 and PGE2 were observed
[12,13] and the hypertensive effect of NOS blockade
was increased by pretreatment with indomethacin [14].
Nitrovasodilator drugs and NO were shown to suppress
vascular prostacyclin release [15]. Therefore, it is not
surprising that prostacyclin can very effectively substi-
tute NO during chronic NOS blockade or after dele-
tion of the eNOS gene. Flow-dependent dilation of rat
gracilis muscle arterioles and acetylcholine-induced
relaxation of mesenteric arteries, the responses of which
are normally mediated by endothelium-derived NO,
remain unaltered in eNOS knockout mice [16,17].
However, indomethacin, which has no or weak effect on
vessels prepared from wild-type animals, almost comple-
tely abolishes the above-mentioned responses after
eNOS gene deletion [16,17], indicating that prostacyclin
or other prostanoids compensate for the loss of NO.
Numerous studies have shown the compensatory role
of vasodilator prostanoids in the coronary circulation in
NO deficiency. In canine and rabbit coronary arteries,
endothelium-dependent relaxations by acetylcholine
Fig. 2
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were not affected significantly by in-vitro COX blockade
[18,19]. In contrast, NOS inhibition induced a signi-
ficant reduction of these vascular responses, the effect
of which was aggravated by simultaneous administration
of indomethacin or diclofenac. These results indicate
that in the absence of NO, the compensatory release of
a vasodilator prostanoid may significantly contribute to
the mediation of endothelium-dependent relaxations in
the coronary artery [18,19]. Indeed, in isolated perfused
hearts, increased release of PGI2 and PGE2 has been
demonstrated after NOS blockade and indomethacin
aggravated the effect of NOS inhibition on the coronary
circulation [3–5].
The mechanism of the adaptation of the cerebral
circulation to NO deficiency is far less understood
although eNOS knockout mice show normal blood flow
not only in the heart [20] but also in the brain [21],
indicating the presence of effective compensatory
mechanisms. Vasodilator prostanoids, released constitu-
tively from brain microvessels, are apparently involved
in the maintenance of the resting cerebral blood flow
in some species including humans and rats [22] and
enhancement of their influence may serve as a reserve
regulatory mechanism in NO deficiency. In this study, we
observed a significant increase in the levels of PGI2 and
PGE2 in the CSF after NOS blockade, which indicates
the activation of a prostanoid-mediated compensatory
mechanism in NO deficiency. Surprisingly, however, the
CBF-decreasing effect of indomethacin failed to increase
in the absence of NO. This apparent discrepancy can
be explained by a dual action of COX blockade. It has
been shown recently in cultured porcine cerebrovascular
endothelial cells that NOS blockade enhances the release
of thromboxane A2 [23] and previous studies indicated
that thromboxane receptors mediate the cerebral vaso-
constriction induced by inhibition of NO synthesis
[24,25]. Therefore, in the absence of NO, both the
vasodilator (PGI2 and PGE2) and vasoconstrictor (throm-
boxane A2) prostanoid pathways seem to be activated
and therefore the CBF effect of COX blockade remains
unaltered. This, however, does not mean that the adverse
cerebrovascular effects of COX inhibitors are not
enhanced in NO deficiency. Our observations show that
the resting CBF is decreased by 22% and COX blockade
induces a further 26% reduction in the absence of NO.
As the oxygen extraction fraction of the resting brain
tissue is relatively high (>40%), COX inhibition in NO-
deficient pathophysiological states may lead to neuronal
hypoxia with its harmful functional consequences.
Conclusion
We conclude that although cerebral release of vasodilator
prostanoids is enhanced after the inhibition of NOS,
they play an equally potent role in the maintenance
of the resting CBF under physiological conditions and
in NO deficiency. As both NOS and COX blockade result
in significant CBF reduction and their cerebrovascular
effects are additive, COX inhibitors may induce cerebral
ischemia in pathological states associated with dimin-
ished NO availability.
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